1
|
Marascio N, Pantanella M, Pavia G, Mazzei C, Di Salvo S, Trimboli F, Barreca GS, Lamberti AG, De Siena M, Gravina T, Matera G, Quirino A. Molecular characterization of autochthonous Hepatitis E virus detected from a human acute infection in the Calabria Region, Southern Italy. Diagn Microbiol Infect Dis 2025; 112:116807. [PMID: 40132339 DOI: 10.1016/j.diagmicrobio.2025.116807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 03/14/2025] [Accepted: 03/17/2025] [Indexed: 03/27/2025]
Abstract
Herein, we reported the molecular characterization of HEV autochthonous strain from an immunocompetent patient. The HEV was classified as subtype 3c and displayed the V1479I ribavirin resistance mutation. The phylogenetic tree analysis showed two statistically supported clusters, including viral strains from symptomatic patients, without severe disease, and meat products.
Collapse
Affiliation(s)
- Nadia Marascio
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Marta Pantanella
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Grazia Pavia
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Chiara Mazzei
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | | | - Francesca Trimboli
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Giorgio S Barreca
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Angelo G Lamberti
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Massimo De Siena
- Unit of Hepatology, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Tiziana Gravina
- Unit of Hepatology, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| | - Giovanni Matera
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy.
| | - Angela Quirino
- Department of Health Sciences, Clinical Microbiology Unit, "Renato Dulbecco" University Hospital, Catanzaro, Italy
| |
Collapse
|
2
|
Dong R, Luo Z, Xue H, Shao J, Chen L, Jin W, Yang L, Shen C, Xu M, Wu M, Wang J. Development and Validation of an Explainable Machine Learning Model for Warning of Hepatitis E Virus-Related Acute Liver Failure. Liver Int 2025; 45:e70129. [PMID: 40344287 DOI: 10.1111/liv.70129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2024] [Revised: 03/22/2025] [Accepted: 04/28/2025] [Indexed: 05/11/2025]
Abstract
BACKGROUND AND AIMS Early identification of patients with acute hepatitis E (AHE) who are at high risk of progressing to hepatitis E virus-related acute liver failure (HEV-ALF) is crucial for enabling timely monitoring and intervention. This multicentre retrospective cohort study aimed to develop and validate an interpretable machine learning (ML) model for predicting the risk of HEV-ALF in hospitalised patients with AHE in tertiary care settings. METHODS The study cohort included patients admitted to seven tertiary medical centers in Jiangsu, China, between 01 January 2018 and 31 December 2024. Multiple ML algorithms were applied for feature selection and model training. The predictive performance of the models was evaluated in terms of discrimination, calibration and clinical net benefit. The interpretability of the final model was enhanced using the SHapley Additive exPlanations. RESULTS A total of 1912 participants were included in the study. Ten ML models were developed based on seven consensus-selected baseline features, with the survival gradient boosting machine (GBM) demonstrating superior performance compared to the traditional Cox proportional hazards regression model and other relevant models or scores. The GBM model achieved a Harrell's concordance index of 0.853 (95% CI: 0.791-0.914) in the external validation set. To facilitate clinical application, the GBM model was interpreted globally and locally and deployed as a web-based tool using the Streamlit-Python framework. CONCLUSIONS The GBM model demonstrated excellent performance in predicting HEV-ALF risk in hospitalised patients with AHE, offering a promising tool for clinical decision-making.
Collapse
Affiliation(s)
- Rui Dong
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, China
| | - Zhenghan Luo
- Department of Infectious Disease Prevention and Control, Huadong Research Institute for Medicine and Biotechniques, Nanjing, China
| | - Hong Xue
- Department of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China
| | - Jianguo Shao
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China
| | - Lin Chen
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China
| | - Wenjuan Jin
- Department of Infectious Disease, The Affiliated Suzhou Ninth Hospital of Soochow University, Suzhou, China
| | - Lingmei Yang
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China
| | - Chao Shen
- Department of Immunization Program, Nanjing Municipal Center for Disease Control and Prevention, Nanjing, China
| | - Minzhi Xu
- Department of Infectious Disease Prevention and Control, Huadong Research Institute for Medicine and Biotechniques, Nanjing, China
| | - Mengping Wu
- Department of Big Data Center, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People's Hospital of Lianyungang, Lianyungang, China
| | - Jie Wang
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, China
- Department of Nursing, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Nanjing Medical University, Taizhou, China
| |
Collapse
|
3
|
Dimeglio C, Schlosser O, Laperche S, De Smet C, Demmou S, Latour J, Jeanne N, Tribout M, Bleuez N, Figoni J, Abravanel F, Lhomme S, Izopet J. Wastewater Surveillance to Estimate and Characterize Hepatitis E Virus Circulation. FOOD AND ENVIRONMENTAL VIROLOGY 2025; 17:30. [PMID: 40399512 PMCID: PMC12095344 DOI: 10.1007/s12560-025-09644-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2025] [Accepted: 05/05/2025] [Indexed: 05/23/2025]
Abstract
Hepatitis E virus (HEV) is a cause of enterically transmitted hepatitis around the world. Because of the high frequency of asymptomatic infections, the magnitude of HEV infection is underestimated. Wastewater monitoring could be useful to improve our knowledge on HEV epidemiology. In this study, we analyzed the capacity of wastewater surveillance to give an insight into the circulation and the diversity of HEV in two French cities. HEV RNA was detected and quantified by digital PCR in 115 untreated composite wastewater samples collected weekly at the inlet of wastewater treatment plants (WWTPs), 58 at Toulouse WWTP and 57 at Dunkerque WWTP. Plasma HEV RNA in blood donors was detected by a commercial assay (Roche Cobas) over the same period in the same area. HEV diversity was analyzed using long-read single-molecule real-time sequencing (Pacific Biosciences). HEV RNA was detected in 88% and 95% wastewater samples collected at Toulouse (Occitanie region, Southern France) and Dunkerque (Hauts-de-France region, Northern France) WWTPs, respectively. HEV RNA concentration ranged between 4.1 and 5.7 log copies/L and was almost similar between the two sites. A long orf2 fragment of HEV genome (1030 nucleotides) was obtained and sequenced in 45% and 70% of positive HEV RNA wastewater samples collected at Toulouse site and Dunkerque site, respectively. Out of 31 strains identified in Toulouse wastewater, 24 were HEV-3c (77%), 6 were HEV-3f (19%), and 1 was HEV-3h (3%). Out of 55 strains identified in Dunkerque, 30 were HEV-3c (55%) and 25 were HEV-3f (45%). All HEV RNA-positive samples from blood donors that could be genotyped during the study period contained HEV-3. Subtype distribution in 51 blood donors living in Toulouse did not differ from that in Toulouse wastewater. The HEV-3 subtype distribution in 51 Hauts-de-France region blood donors and in Dunkerque wastewater were different, but the predominant subtype was the same (HEV-3c). Lastly, we explored the link between the measurement of viral loads in wastewater and the extent of infection in the served population. Although a good correlation between the peaks of positive HEV RNA estimated in wastewater samples and that observed in blood donors was observed with a lag of + 3 weeks for Toulouse, the correlation was weaker for Dunkerque. Wastewater surveillance system applied locally could be very useful for assessing the HEV infection status of a population.
Collapse
Affiliation(s)
- C Dimeglio
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France.
- INFINITY, INSERM U1291, CNRS 5051, Université Paul Sabatier Toulouse III, Toulouse, France.
| | - O Schlosser
- Suez, Centre International de Recherche sur l'Eau et l'Environnement (CIRSEE), 78230, Le Pecq, France
| | - S Laperche
- Etablissement Français du Sang, 93218, Saint-Denis, France
| | - C De Smet
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
| | - S Demmou
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
| | - J Latour
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
| | - N Jeanne
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
| | - M Tribout
- Etablissement Français du Sang Occitanie, 31059, Toulouse, France
| | - N Bleuez
- Etablissement Français du Sang Nord-Pas-de-Calais, 59012, Lille, France
| | - J Figoni
- Santé Publique France, 94410, Saint-Maurice, France
| | - F Abravanel
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
- INFINITY, INSERM U1291, CNRS 5051, Université Paul Sabatier Toulouse III, Toulouse, France
| | - S Lhomme
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
- INFINITY, INSERM U1291, CNRS 5051, Université Paul Sabatier Toulouse III, Toulouse, France
| | - J Izopet
- Laboratoire de Virologie, Centre National de Référence Virus de l'Hépatite E, CHU Toulouse-Purpan, 31059, Toulouse, France
- INFINITY, INSERM U1291, CNRS 5051, Université Paul Sabatier Toulouse III, Toulouse, France
| |
Collapse
|
4
|
Zhang D, Chen Z, Wu J, Ning N, Chen L, Tian X. Chemotherapy-induced febrile neutropenia followed by acute hepatitis E virus infection in rectal cancer patient with synchronous liver and lung metastasis: a case report. BMC Infect Dis 2025; 25:693. [PMID: 40361031 PMCID: PMC12070571 DOI: 10.1186/s12879-025-11097-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2024] [Accepted: 05/08/2025] [Indexed: 05/15/2025] Open
Abstract
BACKGROUND Hepatitis E virus (HEV) typically induces self-limiting infection but can establish persistent infection, particularly in patients with compromised immune systems. However, the literature on HEV infection in patients undergoing chemotherapy is limited. CASE PRESENTATION A 46-year-old Chinese male patient with rectal cancer underwent ten cycles of chemotherapy and targeted therapy. Routine blood tests revealed grade 4 bone marrow suppression necessitating emergency admission. On the second day following admission, the patient presented with high fever that was determined to be chemotherapy-induced febrile neutropenia (FN). However, despite the recovery of white blood cell counts, the fever persisted, and the levels of aminotransferases and bilirubin continued to rise. Two weeks after admission, next generation sequencing of blood samples revealed evidence of HEV. The patient underwent symptomatic and supportive treatment and was discharged after a 30-day hospitalization. One month after discharge, the transaminase and bilirubin levels were within the normal range. DISCUSSION The fatality rate of FN is alarmingly high. To prevent progression to sepsis syndrome and potential mortality, it is imperative to initiate empirical treatment with broad-spectrum antibiotics. As the differential diagnosis of elevated liver enzymes in immunocompromised patients encompasses a wide range of possibilities, the exclusion of HEV infection is crucial when diagnosing drug-induced liver injury (DILI). CONCLUSION This case highlights the importance of healthcare providers being vigilant in identifying HEV infection in patients with solid tumors who experience FN and DILI. Early implementation of comprehensive supportive treatment is crucial for reducing the duration of disease and enhancing patient prognosis.
Collapse
Affiliation(s)
- Dongdong Zhang
- Peking University First School of Clinical Medicine, Peking University First Hospital, Beijing, People's Republic of China
- Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, People's Republic of China
| | | | - Jixiang Wu
- Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, People's Republic of China
| | - Ning Ning
- Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, People's Republic of China
| | - Lin Chen
- Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, People's Republic of China
| | - Xiaodong Tian
- Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, People's Republic of China.
| |
Collapse
|
5
|
de Colnet C, Aboikoni A, Nacher M, Epelboin L, Michaud C, Barbry A, Izopet J, Le Turnier P. Acute hepatitis E virus infection in adults, Cayenne, French Guiana, 2015-2022. Infect Dis Now 2025; 55:105087. [PMID: 40349922 DOI: 10.1016/j.idnow.2025.105087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2025] [Revised: 05/07/2025] [Accepted: 05/09/2025] [Indexed: 05/14/2025]
Abstract
OBJECTIVES French Guiana (FG), a French overseas territory located in the Amazon region, is characterized by a high level of precariousness, which may be conducive to hepatitis E virus (HEV) transmission, but no recent relevant data exist. PATIENTS AND METHODS We conducted a retrospective study to determine the incidence of acute HEV infection diagnosed at Cayenne Hospital, FG between 2015 and 2022. RESULTS Among 934 tested individuals, 12 had positive anti-HEV IgM (positivity rate of 1.28 % CI95 [0.66-2.23]). RT-PCR was rarely performed and no results was positive. Median age was 41 years and half of the subjects were female. No fulminant hepatitis occurred. Neurological manifestations were reported in two patients. Acute forms of HEV infection were rarely diagnosed during the study period. CONCLUSIONS Earlier and more extensive use of RT-PCR could help to better understand the epidemiology of acute HEV infection. The modes of transmission and genotypes of HEV in FG remain uncertain.
Collapse
Affiliation(s)
- Clotilde de Colnet
- Cayenne Hospital Center, Infectious and Tropical Diseases Unit, Cayenne, French Guiana, France
| | - Alolia Aboikoni
- Cayenne Hospital Center, Department of Hepato-Gastroenterology, Cayenne, French Guiana, France; Cayenne Hospital Center, INSERM Clinical Investigation Center 1424, Cayenne, French Guiana, France
| | - Mathieu Nacher
- Cayenne Hospital Center, INSERM Clinical Investigation Center 1424, Cayenne, French Guiana, France; INSERM UA 17 Santé des Populations en Amazonie, France
| | - Loïc Epelboin
- Cayenne Hospital Center, Infectious and Tropical Diseases Unit, Cayenne, French Guiana, France; Cayenne Hospital Center, INSERM Clinical Investigation Center 1424, Cayenne, French Guiana, France; INSERM UA 17 Santé des Populations en Amazonie, France
| | - Céline Michaud
- Cayenne Hospital Center, Remote Prevention and Care Centers, Cayenne, French Guiana, France
| | | | - Jacques Izopet
- National Reference Center for Hepatitis E Virus, Toulouse, France
| | - Paul Le Turnier
- Cayenne Hospital Center, Infectious and Tropical Diseases Unit, Cayenne, French Guiana, France; Cayenne Hospital Center, INSERM Clinical Investigation Center 1424, Cayenne, French Guiana, France; INSERM UA 17 Santé des Populations en Amazonie, France.
| |
Collapse
|
6
|
Magri MC, Manchiero C, Dantas BP, Bernardo WM, Abdala E, Tengan FM. Prevalence of hepatitis E in Latin America and the Caribbean: A systematic review and meta-analysis. Public Health 2025; 244:105745. [PMID: 40347681 DOI: 10.1016/j.puhe.2025.105745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2024] [Revised: 12/20/2024] [Accepted: 04/25/2025] [Indexed: 05/14/2025]
Abstract
OBJECTIVE To estimate the prevalence of hepatitis E virus (HEV) infection by the presence of anti-HEV IgG antibodies in Latin America and the Caribbean (LAC). STUDY DESIGN Systematic review and meta-analysis. METHODS Systematic searches were conducted in the Medline, Lilacs and Embase databases, selecting 81 studies comprising 38,951 individuals in accordance with the PRISMA Statement. Analyses were performed by using the random-effects model. Data analysis considered study cohort and geographic location. RESULTS The prevalence of hepatitis E in LAC ranged from 0 % to 36 % and the overall prevalence was 9.0 %, with important heterogeneity (I2 = 97.3 %). Meta-analysis of subgroups showed prevalence of hepatitis E of 9.0 % in the general population, 6.0 % in blood donors, 9.0 % in rural population, 21.0 % in occupational exposure to pigs, 9.0 % in pregnant women, 7.0 % in immunocompromised individuals, 12.0 % in individuals with chronic liver disease and 9.0 % in individuals with acute hepatitis. According to geographic location, the prevalence of hepatitis E was 7.0 % in Argentina, 16.0 % in Bolivia, 7.0 % in Brazil, 17.0 % in Colombia and 24.0 % in Cuba. The generated funnel plot appeared asymmetric, with evidence of bias according to Egger (p = 0.000) and Begg (p = 0.003) tests. In the analysis, which included only studies with a quality score >5, the prevalence of hepatitis E was 8.0 %. When analysing studies with sample sizes greater than 200 and 500, we identified prevalences of 8.0 % and 7.0 %, respectively. CONCLUSIONS The information obtained in this review warns about the current consolidated prevalence of hepatitis E in LAC, which can be a tool for planning prevention strategies.
Collapse
Affiliation(s)
- Mariana Cavalheiro Magri
- Laboratorio de Investigacao Medica em Hepatologia por Virus (LIM-47), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
| | - Caroline Manchiero
- Laboratorio de Investigacao Medica em Hepatologia por Virus (LIM-47), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Bianca Peixoto Dantas
- Laboratorio de Investigacao Medica em Hepatologia por Virus (LIM-47), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| | | | - Edson Abdala
- Laboratorio de Investigacao Medica em Hepatologia por Virus (LIM-47), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Fátima Mitiko Tengan
- Laboratorio de Investigacao Medica em Hepatologia por Virus (LIM-47), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
| |
Collapse
|
7
|
Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, Lemoine M, Lens S, Testoni B, Lai-Hung Wong G, Russo FP. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2025:S0168-8278(25)00174-6. [PMID: 40348683 DOI: 10.1016/j.jhep.2025.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2025] [Accepted: 03/20/2025] [Indexed: 05/14/2025]
Abstract
The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directions. Chronic HBV remains a global health challenge, with over 250 million individuals affected and significant mortality due to cirrhosis and hepatocellular carcinoma. These guidelines emphasise the importance of early diagnosis, risk stratification based on viral and host factors, and tailored antiviral therapy. Attention is given to simplified algorithms, vaccination, and screening to support global HBV elimination targets. The guidelines also discuss emerging biomarkers and evolving definitions of functional and partial cure. Developed through literature review, expert consensus, and a Delphi process, the guidelines aim to equip healthcare providers across disciplines with practical tools to optimise HBV care and outcomes worldwide.
Collapse
|
8
|
Sasaki-Tanaka R, Kanda T, Yokoo T, Abe H, Hayashi K, Sakamaki A, Kamimura H, Terai S. Hepatitis A and E Viruses Are Important Agents of Acute Severe Hepatitis in Asia: A Narrative Review. Pathogens 2025; 14:454. [PMID: 40430774 DOI: 10.3390/pathogens14050454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2025] [Revised: 04/25/2025] [Accepted: 05/03/2025] [Indexed: 05/29/2025] Open
Abstract
Acute-on-chronic liver failure (ACLF) and acute liver failure (ALF) are severe hepatitis that occur in patients with and without chronic liver diseases and/or cirrhosis, respectively, and both often result in death. Hepatitis A virus (HAV) and hepatitis E virus (HEV) infection can cause these severe conditions. We reviewed the role of HAV and HEV, which infect humans through the fecal-oral route, in ALF and ACLF in Asian countries. This narrative review was the derived from a traditional non-systematic review. Hepatitis A should be recognized as one of the sexually transmitted infections, especially among men who have sex with men. HAV genotype IIIA infection seems to present a more severe clinical manifestation. Acute HEV-1 infection is associated with ALF in pregnant women in India. HEV-4, rather than HEV-3, was found in severe hepatitis in Japan. HEV also plays a role as a cause of acute insult and/or chronic liver disease in immunocompromised patients with ACLF. Further studies are needed for the development of vaccines and antivirals against HAV and HEV infections. Despite the limitations of the recording of cases and the extent of specific vaccinations, multidisciplinary cooperation, involving hepatologists, virologists, experts in public health, etc., may improve the treatment of HAV and HEV infection.
Collapse
Affiliation(s)
- Reina Sasaki-Tanaka
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Tatsuo Kanda
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
- Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Uonuma Kikan Hospital, Minami-Uonuma, Niigata 949-7302, Japan
| | - Takeshi Yokoo
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Hiroyuki Abe
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Kazunao Hayashi
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Akira Sakamaki
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Hiroteru Kamimura
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Shuji Terai
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| |
Collapse
|
9
|
Mikulska M, van Bömmel F, Mouliade C, Indolfi G, Kefalakes H, von Lilienfeld-Toal M, Pischke S, Hermine O, Moradpour D, Wedemeyer H, Berg T, Ljungman P, Mallet V. Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9). Lancet Haematol 2025; 12:e389-e399. [PMID: 40306834 DOI: 10.1016/s2352-3026(25)00049-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Revised: 01/09/2025] [Accepted: 02/14/2025] [Indexed: 05/02/2025]
Abstract
Viral hepatitis remains a global health challenge and immune status affects outcomes. In patients with haematological malignancies, including haematopoietic stem-cell transplantation recipients, viral hepatitis can be life-threatening due to the direct effects of the virus or the need to modify or delay chemotherapy. Additionally, haematopoietic stem-cell donors with past or current viral hepatitis infections might transmit the virus to recipients. The growing recognition of hepatitis E virus (HEV), advances in haematological therapies, and the availability of direct-acting antivirals for hepatitis C virus (HCV), led the 2022 9th European Conference on Infections in Leukaemia (ECIL-9) to update the 2013 ECIL-5 guidelines on viral hepatitis. The ECIL organising committee convened a panel of 13 impartial international experts (all authors of this Review) in viral hepatitis, both within and outside the fields of haematological malignancies and immunosuppression. The ECIL-9 panel conducted a review of the literature on hepatitis B virus (HBV), HCV, and HEV, grading the evidence based on the European Society for Clinical Microbiology and Infectious Diseases system. The panel identified key clinical questions and outcomes and built on the recommendations established during ECIL-5. A consensus conference was held in Sofia Antipolis, France, from Sept 15-17, 2022, bringing together 49 experts from 19 countries. The ECIL-9 panel presented the proposed recommendations, which were revised following expert discussions. A final consensus on updated guidelines was reached in a second plenary session. The updated ECIL-9 guidelines provide evidence-based recommendations on the prevention, screening, treatment, and long-term surveillance of viral hepatitis in patients with haematological malignancies and haematopoietic cell transplantation recipients.
Collapse
Affiliation(s)
- Malgorzata Mikulska
- Department of Health Sciences, Division of Infectious Diseases, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - Florian van Bömmel
- Laboratory for Clinical and Experimental Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany; University Liver Tumor Center, Leipzig University Medical Center, Leipzig, Germany
| | - Charlotte Mouliade
- Université Paris Cité, Paris, France; AP-HP Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico-chirurgicales, Service d'Hépatologie, Paris, France
| | | | - Helenie Kefalakes
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
| | - Marie von Lilienfeld-Toal
- Institut für Diversitätsmedizin, Ruhr-Universität Bochum, Bochum, Germany; Hämatologie, Onkologie, Stammzelltransplantation und Zelltherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany; Department of Haematology, Oncology and Palliative Care, St Josef Hospital, Ruhr University, Bochum, Germany
| | - Sven Pischke
- Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Olivier Hermine
- Université Paris Cité, Paris, France; Department of Haematology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Laboratory of Physiopathology of Haematological Disorders and their Treatment, Imagine Institute INSERM U 1163, Paris, France
| | - Darius Moradpour
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Heiner Wedemeyer
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
| | - Thomas Berg
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany
| | - Per Ljungman
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Vincent Mallet
- Université Paris Cité, Paris, France; AP-HP Centre, Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico-chirurgicales, Service d'Hépatologie, Paris, France.
| |
Collapse
|
10
|
Lampejo T. Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)-Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection? Open Forum Infect Dis 2025; 12:ofaf231. [PMID: 40433189 PMCID: PMC12107242 DOI: 10.1093/ofid/ofaf231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2025] [Indexed: 05/29/2025] Open
Abstract
Chronic hepatitis E virus (HEV) infection, which primarily affects the immunocompromised, can rapidly progress to liver fibrosis and cirrhosis if untreated. However, current therapeutic options are extremely limited and have significant adverse effects. Over the past decade, virus-specific T-cell therapy has shown promise as an alternative safe and effective treatment strategy for other refractory viral infections such as cytomegalovirus, adenovirus, and polyomavirus infections in hematopoietic stem cell and solid organ transplant recipients. Given the key role of T lymphocytes in the control of HEV replication and the fact that HEV-specific T-cell responses are typically diminished in immunosuppressed patients with persistent HEV infection, adoptive immunotherapy with HEV-specific T cells could serve as a novel addition to the HEV treatment repertoire, which is in dire need of expansion.
Collapse
Affiliation(s)
- Temi Lampejo
- Faculty of Medicine and Life Sciences, King's College London, London, UK
- Department of Infection Sciences, King's College Hospital, London, UK
| |
Collapse
|
11
|
Drexler S, Haedge F, Weber SN, Krawczyk M, Matter MS, Geppert CI, Weber A, Stieger B, Trautwein C, Kremer AE. Hepatitis E virus infection-triggered intrahepatic cholestasis: A case report. World J Hepatol 2025; 17:92426. [PMID: 40308830 PMCID: PMC12038418 DOI: 10.4254/wjh.v17.i4.92426] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Revised: 06/30/2024] [Accepted: 07/09/2024] [Indexed: 04/25/2025] Open
Abstract
BACKGROUND Genetic disorders affecting hepatobiliary transporters can be triggered by various factors, resulting in marked cholestasis. CASE SUMMARY We report two patients who experienced a severe episode of intrahepatic cholestasis triggered by an acute hepatitis E virus infection. Following an extensive clinical examination that ruled out common causes of cholestatic liver damage, we conducted next-generation sequencing to determine the genetic profiles of the patients. The analysis revealed several known and unknown variants in genes associated with hepatobiliary transporters and bile salt regulation, including ATP8B1, ABCB11, ABCB4, MYO5B, and FXR. For a comprehensive understanding of the pathophysiology, we performed ClinVar analysis and utilized PolyPhen for bioinformatic prediction of functional impact. Both patients exhibited rapid symptom improvement and a decrease in hyperbilirubinemia when treated with either rifampicin or bezafibrate. CONCLUSION Our findings introduce hepatitis E viral infection as a novel trigger for intrahepatic cholestasis, and we categorize the significance of the various genetic variants based on the current state of research.
Collapse
Affiliation(s)
- Stephan Drexler
- Department of Medicine III, University Hospital Aachen, Aachen 52070, Germany.
| | - Frederic Haedge
- Department of Medicine III, University Hospital RWTH Aachen, Aachen 52070, Germany
| | - Susanne N Weber
- Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg 66424, Germany
| | - Marcin Krawczyk
- Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg 66424, Germany
- Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen 45307, Germany
| | - Matthias S Matter
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel 4031, Switzerland
| | - Carol I Geppert
- Department of Pathology, Univ Erlangen Nurnberg, Erlangen D-91054, Germany
- Comprehensive Cancer Center Erlangen-EMN (CCC), University Hospital Erlangen, FAU Erlangen-Nuremberg, Erlangen D-91052, Germany
| | - Achim Weber
- Institute of Molecular Cancer Research, University Hospital Zurich and University Zurich, Zurich 8091, Switzerland
| | - Bruno Stieger
- Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zurich 8091, Switzerland
| | - Christian Trautwein
- Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen 52070, Germany
| | - Andreas E Kremer
- Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zurich 8091, Switzerland
- Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen 91054, Germany
| |
Collapse
|
12
|
Kanda T, Sasaki-Tanaka R, Yokoo T, Hayashi K, Kamimura H, Tsuchiya A, Terai S. Cholestasis in hepatitis E virus infection. World J Hepatol 2025; 17:99899. [PMID: 40308815 PMCID: PMC12038413 DOI: 10.4254/wjh.v17.i4.99899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2024] [Revised: 09/21/2024] [Accepted: 10/09/2024] [Indexed: 04/25/2025] Open
Abstract
Hepatitis E virus (HEV) infection causes acute hepatitis, chronic hepatitis, particularly in compromised hosts, and various extrahepatic manifestations. HEV infection is reportedly associated with biliary-pancreatic diseases, such as gallstones, cholangitis, choledocholithiasis, and acute pancreatitis. Severe jaundice and prolonged cholestasis are also atypical manifestations of HEV infection. The mechanism and genes involved in cholestasis, namely sinusoidal uptake of blood, bile salt synthesis and secretion from hepatocytes to the canaliculus, have been elucidated. HEV infection triggers severe jaundice and prolonged cholestasis in patients with genetic variants in adenosine triphosphatase phospholipid transporting 8B1, adenosine triphosphate-binding cassette (ABC) protein B4, ABCB11, Myosin VB, and/or farnesoid X receptor (FXR/NR1H4). Although prolonged cholestasis associated with these gene mutations does not seem to be specific to HEV infection, these mutations may be risk factors related to the severity of HEV infection. The use of the pregnane X receptor agonist rifampicin and the peroxisome proliferator-activated receptor activator bezafibrate may be useful for the treatment of cholestasis. These studies provide new insights into understanding the mechanisms of severe jaundice and prolonged cholestasis caused by HEV infection.
Collapse
Affiliation(s)
- Tatsuo Kanda
- Division of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma 949-7302, Niigata, Japan.
| | - Reina Sasaki-Tanaka
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Takeshi Yokoo
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Kazunao Hayashi
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Hiroteru Kamimura
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Atsunori Tsuchiya
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| | - Shuji Terai
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan
| |
Collapse
|
13
|
Viera-Segura O, Duarte-López IX, Loera-Robles I, Singh-Ríos N, Calderón-Flores A, Copado-Villagrana ED, Fierro NA. Chronic Hepatitis E Virus Infection Without Liver Injury in a Patient with Chronic Kidney Disease. Pathogens 2025; 14:420. [PMID: 40430741 DOI: 10.3390/pathogens14050420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2025] [Revised: 04/22/2025] [Accepted: 04/24/2025] [Indexed: 05/29/2025] Open
Abstract
Hepatitis E virus (HEV), the causative agent of hepatitis E, is the leading cause of acute viral hepatitis worldwide; under immunosuppression, infection can lead to chronic liver disease. Furthermore, extrahepatic manifestations, particularly renal manifestations, are frequently associated with infection. This is important considering the global burden of chronic kidney disease (CKD). However, the study of chronic hepatitis E has been limited to liver disease, and its definition with respect to renal disease is still incomplete. Recently, through a protocol aimed at identifying HEV seroprevalence in a cohort of patients on hemodialysis, we incidentally identified HEV RNA in a patient with a history of alcoholism, diabetes mellitus, and essential systemic hypertension. In this study, we aimed to follow up this case to characterize hepatitis E in the context of CKD. Notably, we identified the development of chronic HEV genotype 3 infection without seroconversion or evidence of liver damage. Moreover, apparent immunocompetence was identified in the patient. Considering that HEV is still neglected in numerous countries and that it is not included in the differential diagnosis of kidney disease, our findings support the need to consider HEV infection in patients with renal disease, even in the absence of liver deterioration.
Collapse
Affiliation(s)
- Oliver Viera-Segura
- Instituto en Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - Ilsy X Duarte-López
- Unidad de Medicina Familiar 5, Instituto Mexicano del Seguro Social, Nogales 84000, Mexico
| | - Isidro Loera-Robles
- Unidad de Medicina Familiar 5, Instituto Mexicano del Seguro Social, Nogales 84000, Mexico
| | - Norberto Singh-Ríos
- Unidad de Medicina Familiar 5, Instituto Mexicano del Seguro Social, Nogales 84000, Mexico
| | - Arturo Calderón-Flores
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | | | - Nora A Fierro
- Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| |
Collapse
|
14
|
Brüggemann Y, Frericks N, Richter E, Kinast V, Steinmann E. How hepatitis E virus invades hepatocytes: the mystery of viral entry. Trends Microbiol 2025:S0966-842X(25)00111-8. [PMID: 40274493 DOI: 10.1016/j.tim.2025.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2025] [Revised: 03/28/2025] [Accepted: 03/31/2025] [Indexed: 04/26/2025]
Abstract
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis globally. HEV infections can progress to chronic disease in immunocompromised individuals and may also cause extrahepatic complications. By contrast to other hepatitis viruses, HEV exhibits a broad tissue tropism, and certain genotypes have the ability to infect multiple species. The initial steps of surface attachment and host cell entry are critical steps in the viral infection cycle and serve as key determinants to establish an infection. This review summarizes the current understanding of HEV entry, focusing on molecular entry factors, such as viral receptors, and discusses differences between quasi-enveloped and non-enveloped HEV. We further cover recent developments of assay systems to study HEV entry and highlight experimental strategies to identify novel host components required for HEV entry. Advancing our understanding in these areas could help to guide the development of targeted antiviral strategies to block the early stages of HEV infection.
Collapse
Affiliation(s)
- Yannick Brüggemann
- Department of Molecular and Medical Virology, Faculty of Medicine, Ruhr University Bochum, Bochum, Germany
| | - Nicola Frericks
- Department of Molecular and Medical Virology, Faculty of Medicine, Ruhr University Bochum, Bochum, Germany
| | - Emely Richter
- Department of Molecular and Medical Virology, Faculty of Medicine, Ruhr University Bochum, Bochum, Germany
| | - Volker Kinast
- Department of Medical Microbiology and Virology, Carl von Ossietzky University Oldenburg, Oldenburg, Germany
| | - Eike Steinmann
- Department of Molecular and Medical Virology, Faculty of Medicine, Ruhr University Bochum, Bochum, Germany; German Centre for Infection Research (DZIF), External Partner Site, Bochum, Germany.
| |
Collapse
|
15
|
Daniel R, Zelber-Sagi S, Barak M, Zuckerman E. The Epidemiology of Hepatitis E in Israel and Potential Risk Factors: A Cross-Sectional Population-Based Serological Survey of Hepatitis E Virus in Northern Israel. Viruses 2025; 17:536. [PMID: 40284979 PMCID: PMC12031424 DOI: 10.3390/v17040536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2025] [Revised: 04/01/2025] [Accepted: 04/03/2025] [Indexed: 04/29/2025] Open
Abstract
Hepatitis E Virus (HEV) has gained public health attention as one of the causative agents of viral hepatitis. Our study aimed to provide data about HEV seropositivity in the Israeli general population, including its seroprevalence geographical distribution, and to identify variables as possible risk factors for HEV exposure. A seroprevalence cross-sectional study was conducted: HEV serological status was determined in 716 blood samples collected from the routine check-up blood samples. Demographic information was available for all samples. The overall prevalence of HEV IgG in an apparently healthy population in the north of Israel was 10.5%, with no evidence of positive HEV IgM. There was a significant association between HEV seropositivity and elderly age and low socioeconomic status (SES). The age-adjusted seroprevalence was significantly lower among Jews compared to Arabs with a rate ratio of 2.02. We identified clusters (hot spots) of HEV infection in three regions under study. Our results confirmed a high prevalence of anti-HEV in the country where clinical hepatitis E is not endemic. For the first time, this study showed that a hot spot analysis was able to provide new knowledge about actual exposure zones. As HEV infection is not a notifiable disease, it is probably underdiagnosed. Thus, better awareness among physicians is warranted.
Collapse
Affiliation(s)
- Rasha Daniel
- Haifa and Western Galilee Central Laboratories, Clalit Health Services, Nesher 20300, Israel
| | - Shira Zelber-Sagi
- School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa 3498838, Israel;
| | - Mira Barak
- Head of Medical Laboratory Sciences, Zefat Academic College, Safed 13206, Israel;
| | - Eli Zuckerman
- Liver Unit, Carmel Medical Center, Faculty of Medicine, Technion Institute, Haifa 3498838, Israel
| |
Collapse
|
16
|
Virhuez-Mendoza M, Ishijima K, Tatemoto K, Kuroda Y, Inoue Y, Nishino A, Yamamoto T, Uda A, Hotta A, Kabeya H, Shimoda H, Suzuki K, Komiya T, Seto J, Iwashina Y, Hirano D, Sawada M, Yamaguchi S, Hosaka F, Maeda K. Recent Hepatitis E Virus Infection in Wild Boars and Other Ungulates in Japan. Viruses 2025; 17:524. [PMID: 40284967 PMCID: PMC12031028 DOI: 10.3390/v17040524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2025] [Revised: 04/02/2025] [Accepted: 04/02/2025] [Indexed: 04/29/2025] Open
Abstract
Hepatitis E virus (HEV) is a zoonotic pathogen with multiple hosts, posing significant public health risks, especially in regions like Japan where game meat consumption is prevalent. This study investigated HEV infection and viral shedding in wild boars, sika deer, and Japanese serows across Japan. A total of 1896 serum samples were tested for anti-HEV antibodies, 1034 for HEV RNA, and 473 fecal samples for viral shedding. Anti-HEV antibodies were detected in wild boars from all seven prefectures studied, while HEV RNA was detected in wild boars from Fukuoka, Oita, and Miyazaki in southern Japan, as well as Yamaguchi prefecture. Genetic analysis revealed subtypes 3b, 4a, and 4g, with 3b being the most prevalent. Subtype 3b exhibited distinct geographical clustering, whereas 4g persisted exclusively in Yamaguchi for over 12 years. Infectious HEV particles were confirmed in wild boar feces, highlighting the risk of environmental contamination and zoonotic transmission. Sika deer showed no evidence of HEV infection, and only one Japanese serow tested positive for antibodies without detectable RNA. These findings underscore the importance of ongoing surveillance to assess the zoonotic risks from game meat consumption and prevention of HEV transmission to humans.
Collapse
Affiliation(s)
- Milagros Virhuez-Mendoza
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Keita Ishijima
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Kango Tatemoto
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Yudai Kuroda
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Yusuke Inoue
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Ayano Nishino
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
- Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan
| | - Tsukasa Yamamoto
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
- Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan
| | - Akihiko Uda
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Akitoyo Hotta
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
| | - Hidenori Kabeya
- Laboratory of Veterinary Food Hygiene, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa 252-0880, Japan
| | - Hiroshi Shimoda
- Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan
| | | | - Tomoyoshi Komiya
- Faculty of Health and Medical Sciences, Hokuriku University, Kanazawa 920-1180, Japan
| | - Junji Seto
- Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata 990-0031, Japan
| | - Yuki Iwashina
- Japan Wildlife Research Center, Tokyo 130-8606, Japan
| | - Daisuke Hirano
- Livestock Hygiene Department, Aomori Prefecture Livestock Association, Aomori 030-0822, Japan
| | - Mikio Sawada
- Gifu Veterinary Medical Association, Gifu 500-8385, Japan
| | - Sayuri Yamaguchi
- Kagawa Prefecture Livestock Association, Takamatsu 760-0023, Japan
| | - Fusayo Hosaka
- Gunma Prefecture Livestock Association, Maebashi 379-2147, Japan
| | - Ken Maeda
- Department of Veterinary Science, National Institute of Infectious Diseases (NIID), Tokyo 162-8640, Japan; (M.V.-M.)
- Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan
| |
Collapse
|
17
|
Abravanel F, Vignon C, Mercier A, Gaumery JB, Biron A, Filisetti C, Goujart MA, Colot J, Chamillard X, Demortier J, Raz M, Boutet C, Dupont L, Duval S, Castric C, Desoutter D, Desoutter A, Verge M, De Smet C, Demmou S, Lhomme S, Gourinat AC, Nicot F, Izopet J. Large-scale HEV genotype 3 outbreak on New Caledonia Island. Hepatology 2025; 81:1343-1352. [PMID: 39212522 DOI: 10.1097/hep.0000000000001081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Accepted: 07/31/2024] [Indexed: 09/04/2024]
Abstract
BACKGROUND AND AIMS Several symptomatic cases of HEV infections were reported to the New Caledonia Island Public Health Service between August and December 2023. This prompted epidemiological and virological investigations to identify the source of infection. APPROACH AND RESULTS HEV RNA was assessed in symptomatic patients, various food items, and pig farms on the Island. HEV strains were characterized by sequencing. A seroprevalence study was also conducted on asymptomatic blood donors before and after the outbreak. One hundred twenty-seven symptomatic cases were reported. Hospitalization was required for 29/127 patients (22.8%). Hospitalized patients presented more frequently with comorbidities, including liver and cardiovascular diseases (80.7% vs. 27%, p < 0.01), and 3 persons died (2.3%). Among the 100 HEV RNA-positive samples received at the French National Reference Centre for HEV, viral sequencing was possible for 76 samples. All strains were identified as HEV genotype 3, and 74/76 strains were grouped together (nucleotide identity: 98%-100%). Full-length sequencing indicated a new HEV-3 subtype within HEV-3 subclade abk. Only genotype 3f strains were detected on the Island's pig farms. No food items tested positive for HEV RNA. The seroprevalence of HEV IgG and IgM in blood donors was 9.2% (9/98) and 0%, respectively, in 2020, rising to 17.3% (17/98) and 2% (2/98) in 2024. CONCLUSIONS Although all previous large-scale epidemics in Asia and Africa were associated with HEV-1 or 2, the New Caledonia outbreak was linked to HEV-3. A high number of symptomatic cases were admitted to the hospital, with a case-fatality rate of 2.3%.
Collapse
Affiliation(s)
- Florence Abravanel
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
- Inserm UMR 1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Toulouse
| | - Clémence Vignon
- Toulouse University Hospital, Hopital Rangueil Service d'hépatologie - 1 Avenue du Pr J. Poulhes- Université Paul Sabatier III, Toulouse France, Nouvelle-Calédonie
| | - Ambroise Mercier
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan, Nouméa Cedex
| | - Jean-Baptiste Gaumery
- Direction des Affaires Sanitaire et Sociale, 7 avenue Paul DOUMER, BP M2, NOUMÉA Cedex, Nouvelle-Calédonie
| | - Antoine Biron
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan, Nouméa Cedex
| | - Clément Filisetti
- Direction des Affaires Sanitaire et Sociale, 7 avenue Paul DOUMER, BP M2, NOUMÉA Cedex, Nouvelle-Calédonie
| | - Marie-Amélie Goujart
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan, Nouméa Cedex
| | - Julien Colot
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan, Nouméa Cedex
| | - Xavier Chamillard
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan - BP J5, Nouméa Cedex
| | - Justine Demortier
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan - BP J5, Nouméa Cedex
| | - Maxime Raz
- Territorial Hospital Centre Gaston-Bourret, Service de Transfusion Sanguine 110, boulevard Joseph-Wamytan - BP J5, Nouméa Cedex
| | - Catherine Boutet
- Direction des Affaires Sanitaire et Sociale, 7 avenue Paul DOUMER, BP M2, NOUMÉA Cedex, Nouvelle-Calédonie
| | - Laura Dupont
- Direction des Affaires Sanitaire et Sociale, 7 avenue Paul DOUMER, BP M2, NOUMÉA Cedex, Nouvelle-Calédonie
| | - Sylvie Duval
- Direction des affaires vétérinaires, alimentaires et rurales 2 Rue Felix Russeil, Nouméa, Nouvelle-Calédonie
| | - Catherine Castric
- Direction des affaires vétérinaires, alimentaires et rurales 2 Rue Felix Russeil, Nouméa, Nouvelle-Calédonie
| | - Denise Desoutter
- Direction des affaires vétérinaires, alimentaires et rurales 2 Rue Felix Russeil, Nouméa, Nouvelle-Calédonie
| | - Anais Desoutter
- Direction des affaires vétérinaires, alimentaires et rurales 2 Rue Felix Russeil, Nouméa, Nouvelle-Calédonie
| | - Marjorie Verge
- Direction des affaires vétérinaires, alimentaires et rurales 2 Rue Felix Russeil, Nouméa, Nouvelle-Calédonie
| | - Clémentine De Smet
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
| | - Sofia Demmou
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
| | - Sébastien Lhomme
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
- Inserm UMR 1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Toulouse
| | - Ann-Claire Gourinat
- Direction des Affaires Sanitaire et Sociale, 7 avenue Paul DOUMER, BP M2, NOUMÉA Cedex, Nouvelle-Calédonie
| | - Florence Nicot
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
| | - Jacques Izopet
- Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Laboratoire de Virologie, National Reference Centre for Hepatitis E, Toulouse, France
- Inserm UMR 1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France Toulouse University Hospital, Hôpital Purpan, Place du Dr Baylac, Toulouse
| |
Collapse
|
18
|
An W, Li M, Luo J, Yu Z, Wei H. Prognosis of Acute HEV Infection in Patients With Liver Cirrhosis: A Retrospective Study of 628 Chinese Patients. J Viral Hepat 2025; 32:e14018. [PMID: 39377426 DOI: 10.1111/jvh.14018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2024] [Revised: 09/17/2024] [Accepted: 09/23/2024] [Indexed: 10/09/2024]
Abstract
Acute hepatitis E virus infection is a serious global health problem, which a significant cause of morbidity and mortality. The aim of the present study was to characterise the clinical features and therapeutic response of patients with acute HEV infection and identify risk factors for poor prognosis. In a retrospective study from 01 January 2014 to 01 Januray 2022, we collected baseline data from all patients eligible for acute hepatitis E virus (HEV) infection and followed up with all patients via interviews and medical records. We explored the clinical feature of Chinese patients with acute HEV infection. The follow-up data of patients were used to identify risk factors for poor prognosis. In total, 628 acute hepatitis E (AHE) patients fulfilled the inclusion criteria and did not meet the exclusion criteria. Among them, 452 were males and 176 were females (M:F = 2.57:1). The median age at diagnosis was 57.0 years (interquartile range: 46-64 years). The median baseline serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) were elevated in this cohort (642.3 U/L, 216.2 U/L, 104.1 μmol/L, respectively). The median hospitalisation duration was 16 days. Compared with patients without other liver diseases, patients with liver cirrhosis show lower baseline ALT and AST level, poorer coagulation indices and higher MELD scores. According to multivariate analysis, liver cirrhosis, high MELD score, low albumin concentration was found to be independent predictors of poor prognosis in patients with AHE. Our study used a lager sample size to validate that some demographic and serological features were quite different between patients with/without CLDs. Liver cirrhosis was a significant independent predictor of poor prognosis in acute HEV hepatitis.
Collapse
Affiliation(s)
- Wen An
- Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Mengqi Li
- Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Jing Luo
- Department of Gastroenterology, Peking University Ditan Teaching Hospital, Beijing, China
| | - Zhe Yu
- Department of Gastroenterology, Peking University Ditan Teaching Hospital, Beijing, China
| | - Hongshan Wei
- Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Department of Gastroenterology, Peking University Ditan Teaching Hospital, Beijing, China
| |
Collapse
|
19
|
Baymakova MP, Konaktchieva M, Kunchev M, Popivanov G, Kundurzhiev T, Tsachev I, Mutafchiyski V. First Insight into the Seroprevalence of Hepatitis E Virus and Associated Risk Factors Among Liver Transplant Recipients from Bulgaria. Vector Borne Zoonotic Dis 2025; 25:303-313. [PMID: 39943906 DOI: 10.1089/vbz.2024.0101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2025] Open
Abstract
Introduction: Hepatitis E virus (HEV) infection is caused by viruses belonging to the Hepeviridae family. HEV infection can be self-limiting; however, extrahepatic manifestations may be present. The purpose of the current study was to establish the seroprevalence of HEV among Bulgarian liver transplant recipients (LTRs) and to identify associated risk factors. Materials & Methods: The present study was conducted between April 1, 2023, and October 30, 2023, at the Military Medical Academy, Sofia, Bulgaria. All serum samples were tested for anti-HEV IgG/IgM using HEV IgG/IgM enzyme-linked immunosorbent assay on Dia.Pro (Milan, Italy). Each participating LTR completed a detailed paper-based closed-ended questionnaire regarding the associated risk factors for HEV infection. Results: The study included 73 LTRs with a mean age of 47.0 ± 14.0 years. Anti-HEV IgG antibodies were detected in 25 LTRs (34.2%), including 20 males (37.7%) and 5 females (25%). All participants were HEV-IgM negative. HEV seropositivity rates were higher but not statistically significant in LTRs aged >60 years than in those aged <60 years (40% vs. 32.7%). A significant factor by logistic regression was "high level of education" (odds ratio [OR] = 2.917; p = 0.038). Conclusion: To the best of our knowledge, this is the first seroepidemiological HEV study among LTRs from Bulgaria that found a high seroprevalence (34.2%).
Collapse
Affiliation(s)
| | - Marina Konaktchieva
- Department of Gastroenterology and Hepatology, Military Medical Academy, Sofia, Bulgaria
| | - Metodi Kunchev
- Department of Virology, Military Medical Academy, Sofia, Bulgaria
| | - Georgi Popivanov
- Department of Surgery, Military Medical Academy, Sofia, Bulgaria
| | - Todor Kundurzhiev
- Department of Occupational Medicine, Faculty of Public Health, Medical University, Sofia, Bulgaria
| | - Ilia Tsachev
- Department of Microbiology, Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, Trakia University, Stara Zagora, Bulgaria
| | | |
Collapse
|
20
|
León-Janampa N, Brand D, Marlet J. [Hepatitis E: Epidemiology, pathology and prevention]. Med Sci (Paris) 2025; 41:346-354. [PMID: 40294294 DOI: 10.1051/medsci/2025047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2025] Open
Abstract
Hepatitis E virus (HEV) is a major cause of acute hepatitis. HEV genotypes 1 and 2 are associated with oro-faecal epidemics and fulminant hepatitis in pregnant women. HEV genotypes 3 and 4 are a zoonosis transmitted by uncooked pork. Infection is usually spontaneously resolutive. Chronic hepatitis may occur in immunocompromised patients. Extrahepatic disease is also possible. Prevention is based on hygiene, especially in high-risk patients, and access to safe drinking water for all. A recombinant vaccine against HEV has been developed and is currently being validated by the WHO.
Collapse
Affiliation(s)
- Nancy León-Janampa
- INSERM U1259 MAVIVHe, Université de Tours et CHRU de Tours, Tours, France
| | - Denys Brand
- INSERM U1259 MAVIVHe, Université de Tours et CHRU de Tours, Tours, France
| | - Julien Marlet
- INSERM U1259 MAVIVHe, Université de Tours et CHRU de Tours, Tours, France
| |
Collapse
|
21
|
Binda B, Picchi G, Bruni R, Di Gasbarro A, Madonna E, Villano U, Pisani G, Carocci A, Marcantonio C, Montali F, Panarese A, Pisani F, Ciccaglione AR, Spada E. The Prevalence, Risk Factors, and Outcomes of Hepatitis E Virus Infection in Solid Organ Transplant Recipients in a Highly Endemic Area of Italy. Viruses 2025; 17:502. [PMID: 40284945 PMCID: PMC12031106 DOI: 10.3390/v17040502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Revised: 03/25/2025] [Accepted: 03/26/2025] [Indexed: 04/29/2025] Open
Abstract
Hepatitis E virus (HEV) infection can become chronic in immunocompromised patients, like solid organ transplant recipients (SOTRs). We evaluated HEV prevalence, risk factors, and outcomes among SOTRs in a hyperendemic HEV area. Three hundred SOTRs were enrolled from April to July 2019 and tested for anti-HEV IgM and IgG and HEV RNA. Sixty-three recipients (21%) were positive for any HEV marker. HEV infection was independently associated with older age and pork liver sausage consumption. Three viremic recipients harbored genotype 3e and 3f according to HEV RNA sequencing and phylogenetic analysis. Overall, 10 recipients had markers of active/recent infection (HEV RNA and/or anti-HEV IgM) and were followed up prospectively. Five of them spontaneously resolved their HEV infection. In two recipients, HEV clearance was achieved only through immunosuppression reduction, while three needed ribavirin therapy to achieve virologic resolution. We observed a chronic course in 30% of SOTRs with active/recent HEV infection. No association was found between tacrolimus assumption and chronicization. In conclusion, we found a high prevalence of infection among SOTRs attending a transplant center in a hyperendemic Italian HEV region. Systematic screening for all HEV markers and dietary education for infection control are needed for transplant recipients.
Collapse
Affiliation(s)
- Barbara Binda
- General and Transplant Surgery Department, San Salvatore Hospital, 67100 L’Aquila, Italy;
| | - Giovanna Picchi
- Department of Clinical Medicine, Life, Health and Environmental Sciences-MESVA, University of L’Aquila, 67100 L’Aquila, Italy
- Infectious Diseases Department, ASL VT, PO Ospedale Belcolle Santa Rosa, 01100 Viterbo, Italy
| | - Roberto Bruni
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| | - Alessandro Di Gasbarro
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. D’Annunzio” Chieti-Pescara, 66100 Chieti, Italy;
| | - Elisabetta Madonna
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| | - Umbertina Villano
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| | - Giulio Pisani
- National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanita, 00161 Rome, Italy; (G.P.); (A.C.)
| | - Alberto Carocci
- National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanita, 00161 Rome, Italy; (G.P.); (A.C.)
| | - Cinzia Marcantonio
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| | - Filippo Montali
- General and Transplant Surgery Department, Dipartimento di Scienze Cliniche Applicate e Biotecnologiche-DISCAB, University of L’Aquila, 67100 L’Aquila, Italy; (F.M.); (A.P.); (F.P.)
| | - Alessandra Panarese
- General and Transplant Surgery Department, Dipartimento di Scienze Cliniche Applicate e Biotecnologiche-DISCAB, University of L’Aquila, 67100 L’Aquila, Italy; (F.M.); (A.P.); (F.P.)
| | - Francesco Pisani
- General and Transplant Surgery Department, Dipartimento di Scienze Cliniche Applicate e Biotecnologiche-DISCAB, University of L’Aquila, 67100 L’Aquila, Italy; (F.M.); (A.P.); (F.P.)
| | - Anna Rita Ciccaglione
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| | - Enea Spada
- Department of Infectious Diseases, Istituto Superiore di Sanita, 00161 Rome, Italy; (R.B.); (E.M.); (U.V.); (C.M.); (A.R.C.); (E.S.)
| |
Collapse
|
22
|
Hrabal I, Aliabadi E, Reiche S, Weber S, Holicki CM, Schmid L, Fast C, Schröder C, Gutjahr B, Behrendt P, Groschup MH, Eiden M. Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody. Sci Rep 2025; 15:10795. [PMID: 40155491 PMCID: PMC11953370 DOI: 10.1038/s41598-025-95992-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2024] [Accepted: 03/25/2025] [Indexed: 04/01/2025] Open
Abstract
Hepatitis E virus (HEV) poses a significant risk to human health. In Europe, the majority of HEV infection are caused by the zoonotic genotype 3 (HEV-3), which can cause chronic hepatitis E in immunocompromised patients and those with pre-existing liver disease, and may eventually develop into fatal liver cirrhosis. In this study, we examined the effectiveness of a monoclonal antibody (MAb) treatment strategy using a well established HEV-3 pig model with intravenous infection. For this purpose, nine MAbs raised against the viral capsid protein were generated and the neutralizing activities were compared using in vitro assays. The antibody with the highest neutralizing activity, MAb 5F6A1, was selected for an in vivo study in pigs infected with HEV-3. Following the initial infection of pigs with HEV-3, MAb 5F6A1 was administered intravenously one and seven days post-infection. The results suggest MAb 5F6A1 significantly reduced viremia and virus shedding in pigs infected with HEV-3. This study provides significant insight into the dynamics of HEV infection in pigs and highlights the efficacy of MAb based therapy as an option for treating HEV in porcine hosts and, potentially, humans.
Collapse
Affiliation(s)
- Isabella Hrabal
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Elmira Aliabadi
- Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hannover, Germany
- Helmholz Center for Infection Research GmbH, Braunschweig, Germany
| | - Sven Reiche
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Saskia Weber
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Cora M Holicki
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
- Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Laura Schmid
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
- Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Christine Fast
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Charlotte Schröder
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Benjamin Gutjahr
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
| | - Patrick Behrendt
- Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hannover, Germany
- Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
- German Centre for Infection Research, Partner site Braunschweig-Hannover, Braunschweig, Germany
| | - Martin H Groschup
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany
- German Centre for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Greifswald - Insel Riems, Germany
| | - Martin Eiden
- Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany.
| |
Collapse
|
23
|
Celada-Sendino M, Fernández-de la Varga M, Ordieres-Díaz C, Amor-Martín P, Álvarez-Posadilla M, Huergo-Fernández A. Challenges in the management of chronic hepatitis E in immunocompromised patients: reactivation after treatment with ribavirin. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS 2025. [PMID: 40145901 DOI: 10.17235/reed.2025.11177/2025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/28/2025]
Abstract
Chronic HEV infection is a significant cause of morbidity and mortality in immunocompromised patients, with rapid progression to advanced fibrosis. We present the case of a 71-year-old immunocompromised male with chronic liver disease due to hepatitis E, who experienced several episodes of HEV reactivation despite treatment with ribavirin. Thus, the treatment of the infection involves a challenge due to the lack of validated therapeutic options and the risk of viral reactivation after stopping treatment.
Collapse
|
24
|
Haller IE, Reinwald M, Kah J, Eggert FAM, Schwarzlose-Schwarck S, Jahnke K, Lüth S, Dammermann W. Low Serological Agreement of Hepatitis E in Immunocompromised Cancer Patients: A Comparative Study of Three Anti-HEV Assays. Antibodies (Basel) 2025; 14:27. [PMID: 40265408 PMCID: PMC12015928 DOI: 10.3390/antib14020027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2025] [Revised: 03/12/2025] [Accepted: 03/21/2025] [Indexed: 04/24/2025] Open
Abstract
BACKGROUND/OBJECTIVES Hepatitis E virus (HEV) is one of the leading causes of acute hepatitis, with immunosuppressed individuals, such as oncology patients, being particularly vulnerable to chronic infections that may progress to liver disease or fatal outcomes. Assay variability complicates HEV prevalence assessment in at-risk groups. This study aimed to compare the reliability and concordance of three HEV antibody assays-Wantai, Euroimmun, and Elecsys®-in immunosuppressed oncology patients. METHODS In this prospective pilot study, serum samples were obtained from oncology patients between September 2020 and October 2021. Samples were collected both at baseline (treatment-naive) and during ongoing treatment. A healthy control group was retrospectively included for comparative analysis. Anti-HEV IgM and IgG antibodies were tested in all samples using enzyme-linked immunosorbent assays (Wantai, Euroimmun) and an electrochemiluminescence immunoassay (Elecsys®). Demographic and clinical data, along with information on HEV risk factors, were extracted from medical records and patient questionnaires. RESULTS HEV IgM prevalence ranged from 0% (Wantai) to 6% (Elecsys®), while IgG prevalence was 12% (Euroimmun), 38% (Wantai), and 53% (Elecsys®). Concordance was poor, with Cohen's Kappa values indicating slight to moderate agreement (κ = 0.000-0.553). Patients with hematological malignancies exhibited the highest IgG seroprevalence. Risk factor analysis revealed the highest association between HEV exposure and the consumption of undercooked pork or crop-based agriculture. CONCLUSIONS Significant variability among HEV serological assays highlights the challenges of reliable HEV diagnostics in immunosuppressed oncology patients. Assay selection and improved testing strategies are critical for this high-risk group.
Collapse
Affiliation(s)
- Isabel-Elena Haller
- Department of Gastroenterology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| | - Mark Reinwald
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam,14469 Potsdam, Germany
- Department of Hematology and Oncology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| | - Janine Kah
- Department of Gastroenterology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Franz A. M. Eggert
- Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam,14469 Potsdam, Germany
- Department of Neurosurgery, School for Mental Health and Neuroscience, Maastricht University, 6229 ER Maastricht, The Netherlands
| | - Sandra Schwarzlose-Schwarck
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam,14469 Potsdam, Germany
- Department of Hematology and Oncology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| | - Kristoph Jahnke
- Oncology Specialist Practice Brandenburg, 14772 Brandenburg an der Havel, Germany
| | - Stefan Lüth
- Department of Gastroenterology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| | - Werner Dammermann
- Department of Gastroenterology, University Hospital Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
- Center of Translational Medicine, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany
| |
Collapse
|
25
|
Kogias D, Gavriilidis E, Antoniadou C, Skeva A, Kafalis N, Tsilingiris D, Kanellis G, Panopoulou M, Mitroulis I, Ritis K, Skendros P, Kouklakis G. Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab. J Viral Hepat 2025; 32:e70005. [PMID: 39927678 PMCID: PMC11809126 DOI: 10.1111/jvh.70005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2024] [Revised: 01/06/2025] [Accepted: 01/12/2025] [Indexed: 02/11/2025]
Abstract
Hepatitis E virus (HEV) infection is a frequent cause of acute viral hepatitis. Immunocompromised patients, especially those under anti-CD20 regimens, are prone to chronic or treatment-resistant courses of hepatitis E. We report a case of chronic HEV infection in a 36-year-old man with a history of thrombotic thrombocytopenic purpura treated with rituximab 6 months ago, who presented with new-onset painless jaundice and malaise. Laboratory tests and imaging revealed signs of inflammation and hepatic dysfunction. Due to initial suspicion of autoimmune hepatitis, corticosteroid therapy was started. However, liver biopsy and positive HEV RNA value redefined the diagnosis. Serology tests revealed initially acute infection, which later progressed to chronic hepatitis E infection. Treatment with ribavirin, along with supportive care, achieved significant clinical and laboratory improvement, resolving jaundice, restoring normal transaminase and suppressing HEV RNA values. Further review of the literature highlights the impact of immunosuppression caused by anti-CD20 therapies on HEV infection, as well as the challenges in both treatment and achieving sustained virus clearance in such patients. Moreover, this report underlines the importance of HEV screening in patients with hepatitis who have undergone anti-CD20 therapies, shedding light on a situation that is not well described in the literature and should not be overlooked, even in developed countries.
Collapse
Affiliation(s)
- Dionysios Kogias
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Efstratios Gavriilidis
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Christina Antoniadou
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Aikaterini Skeva
- Department of MicrobiologyDemocritus University of ThraceAlexandroupolisGreece
| | - Nikolaos Kafalis
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Dimitrios Tsilingiris
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - George Kanellis
- Department of HemopathologyEvangelismos General HospitalAthensGreece
| | - Maria Panopoulou
- Department of MicrobiologyDemocritus University of ThraceAlexandroupolisGreece
| | - Ioannis Mitroulis
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Konstantinos Ritis
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Panagiotis Skendros
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| | - Georgios Kouklakis
- First Department of Internal MedicineDemocritus University of ThraceAlexandroupolisGreece
| |
Collapse
|
26
|
Wu BY, Tian YX, Zuo J, Yang JR, Fan YC. Global, Regional, and National Burdens of Hepatitis E From 1990 to 2021 and Predicted 2030 Incidence: Results From the Global Burden of Disease Study 2021. J Med Virol 2025; 97:e70279. [PMID: 40019133 DOI: 10.1002/jmv.70279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2024] [Revised: 02/15/2025] [Accepted: 02/19/2025] [Indexed: 03/01/2025]
Abstract
Our objective was to evaluate the shifting burden of hepatitis E virus (HEV) across age groups and geographical scopes from 1990 to 2021 and to predict incidence rates for 2030. Leveraging data from the Global Burden of Diseases 2021, we examined HEV incidence and disability-adjusted life years, calculated average annual percentage changes (AAPCs) and identified pivotal years for incidence trends. We stratified our analysis by age, sex, and sociodemographic index and employed the Bayesian age-period-cohort model to predict future incidence. HEV incidence decreased from 269.68 per 100,000 in 1990 to 260.41 per 100,000 in 2021, with an AAPC of -0.1. Notably, the incidence significantly decreased in 1995, 2006, 2009, and 2014. Southern sub-Saharan Africa presented the most notable increase in HEV infection incidence, increasing from 218.59 per 100,000 individuals (95% [UI] 181.36 to 262.28) to 232.25 per 100,000 individuals (191.9 to 279.82), with an AAPC of 0.2 (95% [CI] 0.2 to 0.2). The 2030 incidence is projected to be 267.44 per 100,000 (95% UI, 235.27 to 299.6). Despite a general decline in HEV incidence associated with health interventions, some regions still report annual increases, underscoring the need for intensified disease management to meet the 2030 goals.
Collapse
Affiliation(s)
- Bai-Yun Wu
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hepatology Institute of Shandong University, Jinan, Shandong, China
| | - Yu-Xin Tian
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hepatology Institute of Shandong University, Jinan, Shandong, China
| | - Jing Zuo
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hepatology Institute of Shandong University, Jinan, Shandong, China
| | - Jie-Ru Yang
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hepatology Institute of Shandong University, Jinan, Shandong, China
| | - Yu-Chen Fan
- Department of Hepatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Hepatology Institute of Shandong University, Jinan, Shandong, China
| |
Collapse
|
27
|
Schwarz M, Mozayani B, Trauner M, Stättermayer AF. Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis. Br J Haematol 2025; 206:977-980. [PMID: 39506930 DOI: 10.1111/bjh.19892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2024] [Accepted: 10/30/2024] [Indexed: 11/08/2024]
Affiliation(s)
- Michael Schwarz
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Behrang Mozayani
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - Michael Trauner
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| | - Albert Friedrich Stättermayer
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
28
|
Ankavay M, Da Silva N, Pollán A, Oechslin N, Dinkelborg K, Behrendt P, Moradpour D, Gouttenoire J. Monitoring of hepatitis E virus infection and replication by functional tagging of the ORF2 protein. JHEP Rep 2025; 7:101293. [PMID: 39991067 PMCID: PMC11847060 DOI: 10.1016/j.jhepr.2024.101293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 11/25/2024] [Accepted: 11/28/2024] [Indexed: 02/25/2025] Open
Abstract
Background and Aims Hepatitis E virus (HEV) infection is a leading cause of acute hepatitis worldwide. Understanding of the mechanisms underlying productive HEV infection remains incomplete and would benefit from technological advances improving current model systems. Methods We exploited transposon-mediated random insertion and selection of viable clones to identify sites in the HEV open reading frame 2 (ORF2) protein, corresponding to the viral capsid, allowing for the insertion of reporter sequences in a functional context. Results Short sequence insertions (5 amino acids) were tolerated at four distinct sites in the C-terminal region of the ORF2 protein, without significantly affecting viral capsid expression and subcellular localization as well as virus production. Full-length HEV genomes harboring larger sequence insertions such as an HA epitope tag, a highly sensitive miniaturized luciferase reporter (HiBiT) or a split GFP at these sites conserved their ability to produce infectious virus, with about a 1-log decrease in viral titers. Findings were confirmed in two different HEV genotype 3 clones. In addition, we demonstrate that HiBiT-tagged HEV, offering rapid and several-log amplitude detection, can be used for the evaluation of antiviral drugs and neutralizing antibodies. Conclusions We describe a convenient, quantitative and potentially scalable system for the monitoring of HEV infection and replication in tissue culture. Impact and implications Hepatitis E virus infection is one of the most frequent causes of acute hepatitis and jaundice worldwide. As treatment options are limited and a vaccine is not universally available, the development of molecular tools to facilitate the identification of new therapeutic strategies is crucial. Based on a screening approach to identify viable insertion sites in the viral genome, we describe a versatile system for preparing recombinant viruses harboring split-reporter tags, i.e. luciferase and GFP. Proof-of-concept experiments revealed that convenient and quantitative monitoring of viral infection and replication is possible with this system, allowing for the evaluation of antiviral drugs and neutralizing antibodies.
Collapse
Affiliation(s)
- Maliki Ankavay
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Nathalie Da Silva
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Angela Pollán
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Noémie Oechslin
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Katja Dinkelborg
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School and Institute for Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany
| | - Patrick Behrendt
- Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School and Institute for Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany
| | - Darius Moradpour
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jérôme Gouttenoire
- Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
29
|
Mirzaev UK, Yoshinaga Y, Baynazarov M, Ouoba S, Ko K, Phyo Z, Chhoung C, Akuffo GA, Sugiyama A, Akita T, Takahashi K, Fukuma S, Tanaka J. Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta-analysis. Hepatol Res 2025; 55:346-362. [PMID: 39487829 DOI: 10.1111/hepr.14132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Revised: 09/27/2024] [Accepted: 10/16/2024] [Indexed: 11/04/2024]
Abstract
AIM Hepatitis E virus (HEV) is a major global health issue, with an estimated 20 million infections annually. Although polymerase chain reaction (PCR) is the diagnostic gold standard due to its precision, it is expensive and technically demanding. Antibody tests offer a more practical and cost-effective alternative, although their accuracy can vary due to factors, such as test manufacturer, antigen composition, HEV genotype, and host immune status. METHODS A comprehensive search was conducted in PubMed, Cochrane, Scopus, and Web of Science databases. Studies included comparing the sensitivity and specificity of immunoglobulin M or immunoglobulin G antibody tests to PCR. Exclusion criteria were non-PCR comparisons, sample sizes under 10, IgA or antigen tests, non-human samples, or missing sensitivity and specificity data. Only English-language full-texts or abstracts were considered. Data analysis was performed using Meta-DTA v2.1.1 and Stata 16.0. RESULTS The meta-analysis evaluated 8054 blood samples from 21 studies. Immunoglobulin M antibody tests demonstrated an overall sensitivity of 83% (95% CI 76-88) and specificity of 98% (95% CI 97-99). Immunoglobulin G tests showed a sensitivity of 74% (95% CI 62-82) and specificity of 89% (95% CI 84-93). Among manufacturers, Wantai was the most accurate for immunoglobulin M detection, whereas MP led for immunoglobulin G. Notably, test sensitivity improved when the test protein genotype aligned with the HEV genotype. CONCLUSION This meta-analysis confirmed that antibody assays have a good sensitivity and high specificity to detect HEV infection in situations where PCR is not feasible, highlighting their potential as a practical diagnostic tool.
Collapse
Affiliation(s)
- Ulugbek Khudayberdievich Mirzaev
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
- Department of Hepatology, Research Institute of Virology, Tashkent, Uzbekistan
| | - Yayoi Yoshinaga
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Mirzarakhim Baynazarov
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
- Department of Hepatology, Research Institute of Virology, Tashkent, Uzbekistan
| | - Serge Ouoba
- Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Sciences de La Santé (IRSS), Nanoro, Burkina Faso
| | - Ko Ko
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Zayar Phyo
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Chanroth Chhoung
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Golda Ataa Akuffo
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Aya Sugiyama
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Tomoyuki Akita
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Kazuaki Takahashi
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| | - Shingo Fukuma
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Junko Tanaka
- Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
30
|
Mallet V, Torres HA. Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges. Br J Haematol 2025; 206:1020-1021. [PMID: 39622628 DOI: 10.1111/bjh.19931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Accepted: 11/19/2024] [Indexed: 03/08/2025]
Abstract
Cancer patients with haematological malignancies are at risk for chronic hepatitis E virus infection following chimeric antigen receptor (CAR) T-cell therapy. Strong clinical suspicion is essential for the early diagnosis and prompt treatment of this difficult-to-treat type of viral hepatitis. Commentary on: Schwarz et al. Chronic hepatitis E in a patient after CAR-T cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis. Br J Haematol 2025; 206:977-980.
Collapse
Affiliation(s)
- Vincent Mallet
- Service Hépatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris Université Paris Cité, Paris, France
| | - Harrys A Torres
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
31
|
Wang B, Cronin P, Mah MG, Yang XL, Su YCF. Genetic Diversity and Molecular Evolution of Hepatitis E Virus Within the Genus Chirohepevirus in Bats. Viruses 2025; 17:339. [PMID: 40143268 PMCID: PMC11945734 DOI: 10.3390/v17030339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2025] [Revised: 02/26/2025] [Accepted: 02/27/2025] [Indexed: 03/28/2025] Open
Abstract
Hepatitis E virus (HEV) is a major zoonotic pathogen causing hepatitis E, with strains identified in various animal species, including pigs, wild boar, rabbits, deer, camels, and rats. These variants are capable of crossing species barriers and infecting humans. HEV belongs to the family Hepeviridae, which has recently divided into two subfamilies: Orthohepevirinae and Parahepevirinae, and five genera: Paslahepevirus, Avihepevirus, Rocahepevirus, Chirohepevirus, and Piscihepevirus. Recent advances in high-throughput sequencing, particularly of bat viromes, have revealed numerous HEV-related viruses, raising concerns about their zoonotic potential. Bat-derived HEVs have been classified into the genus Chirohepevirus, which includes three distinct species. In this study, we analyzed 64 chirohepevirus sequences from 22 bat species across six bat families collected from nine countries. Twelve sequences represent complete or nearly complete viral genomes (>6410 nucleotides) containing the characteristic three HEV open reading frames (ORFs). These strains exhibited high sequence divergence (>25%) within their respective host genera or species. Phylogenetic analyses with maximum likelihood methods identified at least seven distinct subclades within Chirohepevirus, each potentially representing an independent species. Additionally, the close phylogenetic relationship between chirohepevirus strains and their bat hosts indicates a pattern of virus-host co-speciation. Our findings expand the known diversity within the family Hepeviridae and provide new insights into the evolution of bat-associated HEV. Continued surveillance of chirohepevirus will be essential for understanding its potential for zoonotic transmission and public health risks.
Collapse
Affiliation(s)
- Bo Wang
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; (P.C.); (M.G.M.)
| | - Peter Cronin
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; (P.C.); (M.G.M.)
| | - Marcus G. Mah
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; (P.C.); (M.G.M.)
| | - Xing-Lou Yang
- Key Laboratory of Genetic Evolution & Animal Models, Yunnan International Joint Laboratory of Zoonotic Viruses, Yunnan Key Laboratory of Biodiversity Information, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China;
| | - Yvonne C. F. Su
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; (P.C.); (M.G.M.)
| |
Collapse
|
32
|
Lu J, Li Q, Zhang C, Li Z, Guo Q, Cao Z, Yao YF, Xie Q. Heterogeneity in the seroprevalence of hepatitis E virus among hospital attendees: a retrospective study in Shanghai, China. Infect Dis (Lond) 2025:1-11. [PMID: 40017260 DOI: 10.1080/23744235.2025.2471819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2024] [Revised: 02/11/2025] [Accepted: 02/20/2025] [Indexed: 03/01/2025] Open
Abstract
BACKGROUND Hepatitis E virus (HEV) infection is endemic in China. However, there are scarce data of HEV infection among hospital attendees seeking medical treatment or examination for various reasons. OBJECTIVE We aim to investigate the prevalence and incidence of HEV infection by time, age, sex, and across departments in a tertiary hospital. METHODS Paired results of anti-HEV immunoglobulin G (IgG) and IgM of 31,181 unique subjects during 2021-2022 were analysed. RESULTS Overall seropositivity (95% confidence interval) of anti-HEV IgG and IgM was 41.25% (40.71%-41.80%) and 2.35% (2.19%-2.53%), respectively. Acute hepatitis E was more prevalent during winter-early spring and among adults aged 31-70. Anti-HEV IgG seroprevalence increased with age, levelling off at > 60 years of age. Not only the seropositivity, but also the levels of anti-HEV IgG were significantly lower in women than men of middle and old age. Young patients from the Department of Neurology had a significantly higher ratio of past HEV infection, while patients with manifestations of hepatitis, gastrointestinal symptoms or hematological diseases had higher seropositivity of anti-HEVIgM and should have high priority to HEV screening. CONCLUSION Heterogeneity of HEV seroprevalence was noted at different times of the year, between sexes, among age groups and across departments in general hospital. The concentration of HEV-infected patients in a few departments supports a more focused screening strategy in health-care settings.
Collapse
Affiliation(s)
- Jie Lu
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Li
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chenxi Zhang
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ziqiang Li
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Guo
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zhujun Cao
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yu-Feng Yao
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Laboratory of Bacterial Pathogenesis, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Xie
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
33
|
Dong R, Huang L, Chen L, Xue H, Shao J, Ye C, Yang Y, Xu K, Luo Z, Wang J. The predictive value of fibrosis profiles for hepatitis E virus-related liver failure among hospitalized patients with acute hepatitis E: a retrospective cohort study. BMC Infect Dis 2025; 25:255. [PMID: 39988662 PMCID: PMC11849170 DOI: 10.1186/s12879-025-10632-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2025] [Accepted: 02/12/2025] [Indexed: 02/25/2025] Open
Abstract
BACKGROUND Hepatitis E virus (HEV) infection is an important etiology of liver failure. This study aimed to explore the associations of blood fibrosis profiles with HEV-related liver failure (HEV-LF) onset and evaluate their prediction performance in hospitalized patients with acute hepatitis E. METHODS Participants were obtained from two tertiary medical centers in Jiangsu, China, between January 2018 and November 2024. Cox proportional hazards regression, restricted cubic splines, and threshold effect analysis were used to examine associations between fibrosis markers and HEV-LF risk. The predictive value of these markers was evaluated for importance ranking, discrimination, calibration, and net benefit. RESULTS Among 504 included participants, 59 developed HEV-LF during hospitalization. After adjusting for covariates, elevated baseline laminin (HR = 1.432, 95% CI: 1.080-1.900), fibrosis-4 score (HR = 1.865, 95% CI: 1.375-2.530), and aspartate aminotransferase to platelet ratio index (APRI) (HR = 1.603, 95% CI: 1.315-1.954) were associated with a higher HEV-LF risk in a dose-dependent manner. Hyaluronic acid (≤ 740 ng/mL: HR = 1.797, 95% CI: 1.177-2.744) and type IV collagen (≤ 137 ng/mL: HR = 3.075, 95% CI: 1.709-5.533) showed nonlinear associations. APRI was ranked the highest in importance, and its combination with the other two top important markers provided good discrimination (7-day HEV-LF: AUROC = 84.98%, 95% CI: 78.55-91.41; 14-day HEV-LF: AUROC = 80.11%, 95% CI: 73.49-86.73), calibration, and clinical utility for predicting HEV-LF onset. CONCLUSIONS Several blood fibrosis markers are closely associated with HEV-LF risk and have promising predictive value. These findings may inform clinical risk stratification in patients with AHE. TRIAL REGISTRATION Not applicable.
Collapse
Affiliation(s)
- Rui Dong
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Jiangning District, Nanjing, 211166, Jiangsu, China
| | - Lili Huang
- NHC Key Laboratory of Contraceptives Vigilance and Fertility Surveillance/Jiangsu Health Development Research Center, Nanjing, China
| | - Lin Chen
- Nantong Institute of Liver Disease, the Third Affiliated Hospital of Nantong University, Nantong, China
| | - Hong Xue
- Department of Liver Disease, The Third Affiliated Hospital of Nantong University, Nantong, China
| | - Jianguo Shao
- Nantong Institute of Liver Disease, the Third Affiliated Hospital of Nantong University, Nantong, China
| | - Chunyan Ye
- Department of Liver Diseases, The Third People's Hospital of Changzhou, Changzhou, China
| | - Yonglin Yang
- Department of Infectious Diseases, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China
| | - Ke Xu
- Department of Acute Infectious Diseases Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Zhenghan Luo
- Department of Infectious Disease Prevention and Control, Huadong Research Institute for Medicine and Biotechniques, Xuanwu District, Nanjing, 210018, Jiangsu, China.
| | - Jie Wang
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Jiangning District, Nanjing, 211166, Jiangsu, China.
| |
Collapse
|
34
|
Yu B, Zhu Y, Jin Z, Han F, Lv F. A case of thrombotic thrombocytopenic purpura induced by acute hepatitis E and successfully controlled by lymphoplasmapheresis plus rituximab. Virol J 2025; 22:39. [PMID: 39955583 PMCID: PMC11829560 DOI: 10.1186/s12985-025-02649-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2024] [Accepted: 02/03/2025] [Indexed: 02/17/2025] Open
Abstract
BACKGROUND Thrombocytopenia is a common extrahepatic manifestation of hepatitis E virus (HEV) infection and is usually transient and self-limited. Thrombotic thrombocytopenic purpura (TTP) is a rare and lethal blood disorder characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ involvement. The link between HEV infection and TTP is still unclear. CASE PRESENTATION A 74-year-old female was referred to our hospital with complaints of fever, fatigue, nausea and jaundice for 10 days. Liver dysfunction, positive IgM and IgG of HEV, and HEV-RNA viremia prompted the diagnosis of acute hepatitis E, which was followed by a dramatic decline in the platelet count. The presence of schistocytes in the peripheral blood smear, along with decreased ADAMTS13 activity, strongly suggested a diagnosis of TTP. Combination therapy, including 2 courses of lymphoplasmapheresis (LPE), 4 courses of therapeutic plasma exchange, glucocorticoids and rituximab, was applied and contributed to the recovery of platelet. No recurrence of TTP was observed during the follow-up period. To date, this is first patient who developed the initial episode of TTP during the course of HEV viremia. In the meanwhile, LPE was used for the first time in the treatment of HEV-associated TTP. CONCLUSIONS This case highlights the necessity of ruling out TTP in hepatitis E patients with newly developed and severe thrombocytopenia and the values of LPE plus rituximab in treating such patients.
Collapse
Affiliation(s)
- Binfeng Yu
- Department of Liver and Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China
| | - Yongfen Zhu
- Department of Liver and Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China
| | - Zhihua Jin
- Department of Liver and Infectious Diseases, Shaoxing Central Hospital, Shaoxing, China
| | - Fei Han
- Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Fangfang Lv
- Department of Liver and Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
| |
Collapse
|
35
|
Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z, Guo Y, Wang H, Dong E, Xiao J. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Target Ther 2025; 10:33. [PMID: 39904973 PMCID: PMC11794951 DOI: 10.1038/s41392-024-02072-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2024] [Revised: 10/06/2024] [Accepted: 11/12/2024] [Indexed: 02/06/2025] Open
Abstract
As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles in metabolism, detoxification, and immune response. Various factors including viruses, alcohol, metabolites, toxins, and other pathogenic agents can compromise liver function, leading to acute or chronic injury that may progress to end-stage liver diseases. While sharing common features, liver diseases exhibit distinct pathophysiological, clinical, and therapeutic profiles. Currently, liver diseases contribute to approximately 2 million deaths globally each year, imposing significant economic and social burdens worldwide. However, there is no cure for many kinds of liver diseases, partly due to a lack of thorough understanding of the development of these liver diseases. Therefore, this review provides a comprehensive examination of the epidemiology and characteristics of liver diseases, covering a spectrum from acute and chronic conditions to end-stage manifestations. We also highlight the multifaceted mechanisms underlying the initiation and progression of liver diseases, spanning molecular and cellular levels to organ networks. Additionally, this review offers updates on innovative diagnostic techniques, current treatments, and potential therapeutic targets presently under clinical evaluation. Recent advances in understanding the pathogenesis of liver diseases hold critical implications and translational value for the development of novel therapeutic strategies.
Collapse
Affiliation(s)
- Can Gan
- Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
| | - Yuan Yuan
- Aier Institute of Ophthalmology, Central South University, Changsha, China
| | - Haiyuan Shen
- Department of Oncology, the First Affiliated Hospital; The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China
| | - Jinhang Gao
- Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
| | - Xiangxin Kong
- Engineering and Translational Medicine, Medical College, Tianjin University, Tianjin, China
| | - Zhaodi Che
- Clinical Medicine Research Institute and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, China
| | - Yangkun Guo
- Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
| | - Hua Wang
- Department of Oncology, the First Affiliated Hospital; The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China.
| | - Erdan Dong
- Research Center for Cardiopulmonary Rehabilitation, University of Health and Rehabilitation Sciences Qingdao Hospital, School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
- Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
| | - Jia Xiao
- Clinical Medicine Research Institute and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Gastroenterology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
| |
Collapse
|
36
|
Frericks N, Klöhn M, Lange F, Pottkämper L, Carpentier A, Steinmann E. Host-targeting antivirals for chronic viral infections of the liver. Antiviral Res 2025; 234:106062. [PMID: 39716667 DOI: 10.1016/j.antiviral.2024.106062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Revised: 12/18/2024] [Accepted: 12/19/2024] [Indexed: 12/25/2024]
Abstract
Infection with one or several of the five known hepatitis viruses is a leading cause of liver disease and poses a high risk of developing hepatocellular carcinoma upon chronic infection. Chronicity is primarily caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) and poses a significant health burden worldwide. Co-infection of chronic HBV infected patients with hepatitis D virus (HDV) is less common but is marked as the most severe form of chronic viral hepatitis. Hepatitis A virus (HAV) and hepatitis E virus (HEV) primarily cause self-limiting acute hepatitis. However, studies have also reported chronic progression of HEV disease in immunocompromised patients. While considerable progress has been made in the treatment of HCV and HBV through the development of direct-acting antivirals (DAAs), challenges including drug resistance, incomplete viral suppression resulting in failure to achieve clearance and the lack of effective treatment options for HDV and HEV remain. Host-targeting antivirals (HTAs) have emerged as a promising alternative approach to DAAs and aim to disrupt virus-host interactions by modulating host cell pathways that are hijacked during the viral replication cycle. The aim of this review is to provide a comprehensive overview about the major milestones in research and development of HTAs for chronic HBV/HDV and HCV infections. It also summarizes the current state of knowledge on promising host-targeting therapeutic options against HEV infection.
Collapse
Affiliation(s)
- Nicola Frericks
- Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
| | - Mara Klöhn
- Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
| | - Frauke Lange
- Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between Hannover Medical School (MHH) and Helmholtz Centre for Infection Research (HZI), Hannover, Germany
| | - Lilli Pottkämper
- Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
| | - Arnaud Carpentier
- Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between Hannover Medical School (MHH) and Helmholtz Centre for Infection Research (HZI), Hannover, Germany
| | - Eike Steinmann
- Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany; German Centre for Infection Research (DZIF), External Partner Site, Bochum, Germany.
| |
Collapse
|
37
|
Hafkesbrink M, Schemmerer M, Wenzel JJ, Isenmann S. Acute hepatitis E virus infection presenting as meningo-encephalitis. Infection 2025; 53:475-479. [PMID: 39143435 DOI: 10.1007/s15010-024-02361-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2024] [Accepted: 07/22/2024] [Indexed: 08/16/2024]
Abstract
BACKGROUND Acute hepatitis E infection (HEV), with its high incidence in Europe, should be considered as a differential diagnosis of acute viral hepatitis and can in some cases manifest with pronounced neurological symptoms. CLINICAL CASE We report on a 33-year-old female patient with severe arthralgia, myalgia, headache and psychomotor deterioration. Laboratory analyses showed elevated transaminases without signs of cholestasis. Acute hepatitis E virus infection was detected in serum. She reported fatigue and dysesthesias not responsive to analgesics. Cerebrospinal fluid (CSF) analysis revealed an inflammatory syndrome. HEV RNA was detected in the CSF. The infection remained mild, but dysesthesias persisted. Eight weeks after the first admission, the symptoms worsened again. Complete and sustained remission was achieved following intravenous corticosteroid treatment. CONCLUSION In patients with acute neurological symptoms and liver enzyme elevation, HEV infection should be considered. Neurologic symptoms such as fatigue, arthralgia, myalgia and dysesthesia along with psychomotor retardation should prompt CSF analysis.
Collapse
Affiliation(s)
- Moritz Hafkesbrink
- Department of Neurology and Clinical Neurophysiology, GFO Kliniken Niederrhein, St. Josef Hospital, Moers, Germany.
| | - M Schemmerer
- National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Medical Center Regensburg, Regensburg, Germany
| | - J J Wenzel
- National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Medical Center Regensburg, Regensburg, Germany
| | - S Isenmann
- Department of Neurology and Clinical Neurophysiology, GFO Kliniken Niederrhein, St. Josef Hospital, Moers, Germany
| |
Collapse
|
38
|
Kupke P, Kupke M, Borgmann S, Kandulski A, Hitzenbichler F, Menzel J, Geissler EK, Schlitt HJ, Wenzel JJ, Werner JM. Hepatitis E virus infection in immunosuppressed patients and its clinical manifestations. Dig Liver Dis 2025; 57:378-384. [PMID: 38997847 DOI: 10.1016/j.dld.2024.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 06/04/2024] [Accepted: 06/24/2024] [Indexed: 07/14/2024]
Abstract
BACKGROUND & AIMS Hepatitis E virus (HEV) is a main cause of acute hepatitis globally. However, immunosuppressed patients regularly develop chronic courses. The aim of this study was to analyse the current status of HEV diagnostics, characterize clinical manifestations and identify risk factors for complicated HEV infections. METHODS In this retrospective study at two large hospitals, 512 patients with borderline and positive anti-HEV-IgM and 94 patients with positive HEV-PCR between January 1999 and May 2023 were included. RESULTS Detection by anti-HEV-IgM-ELISA led to a positive HEV-PCR in only 17.9 %. Amongst patients with positive HEV-PCR, 61 had underlying immunosuppression and 23 were patients after solid organ transplantation (SOT). All 13 patients with chronic HEV infections were immunosuppressed. Generally, immunosuppression led to higher HEV-RNA concentrations and a higher probability of receiving immediate treatment. However, all fulminant courses with liver failure happened in patients without immunosuppression. Immunocompetent patients showed symptoms more frequently and primarily had higher bilirubin levels indicating more severe liver damage. A risk factor for delayed or failed viral clearance after SOT was the administration of mTOR inhibitors. CONCLUSIONS Fulminant HEV infections happen primarily in immunocompetent patients. Nevertheless, immunosuppressed patients bear the risk of undetected, prolonged HEV infections, reflected by the rare occurrence of symptoms.
Collapse
Affiliation(s)
- Paul Kupke
- Department of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
| | - Maximilian Kupke
- Department of Internal Medicine II, Hospital Ingolstadt, 85049 Ingolstadt, Germany
| | - Stefan Borgmann
- Department of Infectious Diseases and Infection Control, Hospital Ingolstadt, 85049 Ingolstadt, Germany
| | - Arne Kandulski
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Florian Hitzenbichler
- Department of Infection Prevention and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Josef Menzel
- Department of Internal Medicine II, Hospital Ingolstadt, 85049 Ingolstadt, Germany
| | - Edward K Geissler
- Department of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Hans J Schlitt
- Department of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Jürgen J Wenzel
- National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
| | - Jens M Werner
- Department of Surgery, University Hospital Regensburg, 93053 Regensburg, Germany
| |
Collapse
|
39
|
Dudman S, Zerja A, Hasanoğlu İ, Ruta S, van Welzen B, Nicolini LA, Yonga P, Øverbø J, Rawat S, Habibovic S, Kim TB, Rivero-Juarez A, ESGVH members. Global vaccination against hepatitis E virus: position paper from the European Society of Clinical Microbiology and Infectious Diseases Viral Hepatitis Study Group. Clin Microbiol Infect 2025; 31:201-210. [PMID: 39550032 DOI: 10.1016/j.cmi.2024.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2024] [Revised: 11/05/2024] [Accepted: 11/09/2024] [Indexed: 11/18/2024]
Abstract
SCOPE Hepatitis E virus (HEV) is a significant global health issue, impacting both low- and middle-income countries and industrialized nations. HEV genotypes 1 and 2, primarily transmitted through contaminated water, are endemic in low- and middle-income countries, whereas genotypes 3 and 4 are zoonotically transmitted in industrialized regions. Acute HEV infection poses severe risks, particularly to pregnant women and immunocompromised individuals, whereas chronic HEV infection leads to serious complications in those with pre-existing liver disease and transplant recipients. The development of an HEV vaccine offers new prevention opportunities, though its availability and integration into global immunization programmes remain limited. METHODS This position paper was developed by the European Society of Clinical Microbiology and Infectious Diseases Viral Hepatitis Study Group through an extensive review of clinical data, safety profiles, efficacy, and immunogenicity of HEV vaccines. The study group focused particularly on high-risk and special populations, synthesizing global health insights and incorporating recommendations from the Strategic Advisory Group of Experts to formulate strategies for wider HEV vaccination use. QUESTIONS ADDRESSED IN THE POSITION PAPER The position paper evaluates the efficacy and safety of HEV vaccines in both general and special populations. It identifies key barriers to the integration of HEV vaccines into routine immunization programmes, including infrastructure limitations, costs, and vaccine accessibility. The paper also proposes strategies to overcome these challenges and improve vaccine distribution. Furthermore, it addresses ways to enhance public awareness and international cooperation to promote HEV vaccination efforts globally. IMPLICATIONS European Society of Clinical Microbiology and Infectious Diseases Viral Hepatitis Study Group recommends HEV vaccination for high-risk groups, including women of childbearing age, patients with chronic liver diseases, and immunosuppressed individuals. Prioritizing investments in vaccine logistics, integrating diagnostics, and educational outreach can enhance uptake.
Collapse
Affiliation(s)
- Susanne Dudman
- Department of Microbiology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Arjana Zerja
- Department of Infectious Diseases, Hospital University Center "Mother Teresa," Tirana, Albania
| | - İmran Hasanoğlu
- Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
| | - Simona Ruta
- Department of Virology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; Department of Emerging Viral Diseases, "Stefan S. Nicolau" Institute of Virology, Bucharest, Romania
| | - Berend van Welzen
- Department of Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Laura Ambra Nicolini
- Department of Infectious Diseases, Ospedale Policlinico San Martino-IRCC, Genoa, Italy
| | - Paul Yonga
- Department of Infectious Disease and International Health Clinic, Conenect Afya Medlynks Medical Centre and Laboratory, Nairobi, Kenya
| | - Joakim Øverbø
- Department of Microbiology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Norwegian Institute of Public Health, Oslo, Norway
| | - Sumit Rawat
- Department of Microbiology, Bundelkhand Medical College, Sagar, India; Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India
| | - Selma Habibovic
- Department of Microbiology, Public Health Institute Novi Pazar, Novi Pazar, Serbia
| | - Tan Bou Kim
- Department of Intensive Care, Hospital Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - Antonio Rivero-Juarez
- Department of Infectious Diseases, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain; Centro de Investigación Biomédica en Red (CIBER) área de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
| | | |
Collapse
|
40
|
Wang JL, Jiang SW, Hu AR, Shi XJ, Zhou AW, Lin K, Fan Y, Jin MH, Zhang HJ. A model based on chitinase 3-like protein for expecting liver severity of hepatitis B virus infections in the immune tolerance phase. Clin Chim Acta 2025; 567:120085. [PMID: 39667422 DOI: 10.1016/j.cca.2024.120085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2024] [Revised: 11/27/2024] [Accepted: 12/07/2024] [Indexed: 12/14/2024]
Abstract
BACKGROUND The question of whether to treat patients with chronic hepatitis B (CHB) during the immune tolerance (IT) period is a matter of ongoing debate, as it is difficult to discern different levels of liver disease severity. We created and assessed a novel diagnostic model for identifying significant liver tissue damage in individuals with CHB in IT phase. METHODS From November 2018 to December 2022, a cross-sectional study of 311 patients with chronic hepatitis B virus infection (HBV DNA > 30 IU/mL) at Ningbo No. 2 Hospital, Ningbo, China, who underwent liver biopsy, including 44 patients in IT phase. Utilizing univariate regression analyses and logistics analysis, and model was developed and validated to predict the severity of hepatic inflammatory and fibrosis in CHB patients and in IT phase. RESULTS Chitinase 3-like Protein (CHI3L1), albumin (ALB), alanine transaminase (ALT) / aspartate aminotransferase (AST) were identified as independent predictors of liver lesion severity in CHB patients with IT. The three were combined to build the model (named as CAA index), which demonstrated good performance. The CAA index achieved an area under the receiver operating characteristic curve (AUC) of 0.916 (95 % CI, 0.820-1.000) and AUC of validation group was 0.875 (95 % CI, 0.683-1.000). CONCLUSIONS CHI3L1 serves as an independent measure of liver fibrosis and inflammation in CHB. This diagnostic model has some value in assessing the severity of the patient's liver lesion severity and may be a reliable non-invasive diagnostic model helping determine whether treatment is necessary among CHB patients in IT phase.
Collapse
Affiliation(s)
- Jia-Lan Wang
- Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China; Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo 315020, Zhejiang Province, China
| | - Su-Wen Jiang
- Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo 315020, Zhejiang Province, China
| | - Ai-Rong Hu
- Cixi Biomedical Research Institute, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China; Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo 315020, Zhejiang Province, China.
| | - Xiao-Jun Shi
- Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo 315020, Zhejiang Province, China
| | - Ai-Wu Zhou
- Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo 315020, Zhejiang Province, China
| | - Ken Lin
- Ningbo University Health Science Center, Ningbo 315211, Zhejiang Province, China
| | - Ying Fan
- School of Medicine, Shaoxing University, Shaoxing 31200, Zhejiang Province, China
| | - Meng-Han Jin
- Ningbo University Health Science Center, Ningbo 315211, Zhejiang Province, China
| | - Hao-Jin Zhang
- School of Medicine, Shaoxing University, Shaoxing 31200, Zhejiang Province, China
| |
Collapse
|
41
|
Buti M, Ruiz-Cobo JC, Esteban R, Riveiro-Barciela M. Hepatitis E as a trigger for acute-on-chronic liver failure. Clin Mol Hepatol 2025; 31:S196-S204. [PMID: 39523715 PMCID: PMC11925444 DOI: 10.3350/cmh.2024.0758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2024] [Revised: 10/27/2024] [Accepted: 11/07/2024] [Indexed: 11/16/2024] Open
Abstract
Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including progression to acute-on-chronic liver failure (ACLF). Among viral hepatitis types, hepatitis A, E, and B are major causes of ACLF. Active screening and early diagnosis of HEV infection in patients with cirrhosis, especially those who develop ACLF, can improve management and enable timely antiviral therapy. Preventive measures, including HEV vaccination for high-risk groups, could reduce the morbidity and mortality associated with hepatitis E.
Collapse
Affiliation(s)
- Maria Buti
- Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - Juan Carlos Ruiz-Cobo
- Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Rafael Esteban
- Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Mar Riveiro-Barciela
- Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER)
| |
Collapse
|
42
|
Sahin Ozdemir M, Ozdemir YE. Comparison of the performances between ChatGPT and Gemini in answering questions on viral hepatitis. Sci Rep 2025; 15:1712. [PMID: 39799203 PMCID: PMC11724965 DOI: 10.1038/s41598-024-83575-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2024] [Accepted: 12/16/2024] [Indexed: 01/15/2025] Open
Abstract
This is the first study to evaluate the adequacy and reliability of the ChatGPT and Gemini chatbots on viral hepatitis. A total of 176 questions were composed from three different categories. The first group includes "questions and answers (Q&As) for the public" determined by the Centers for Disease Control and Prevention (CDC). The second group includes strong recommendations of international guidelines. The third group includes frequently asked questions on social media platforms. The answers of the chatbots were evaluated by two different infectious diseases specialists on a scoring scale from 1 to 4. Cohen's kappa coefficient was calculated to assess inter-rater reliability. The reproducibility and correlation of answers generated by ChatGPT and Gemini were analyzed. ChatGPT and Gemini's mean scores (3.55 ± 0.83 vs. 3.57 ± 0.89, p = 0.260) and completely correct response rates (71.0% vs. 78.4%, p = 0.111) were similar. In addition, in subgroup analyses with the CDC questions Sect. (90.1% vs. 91.9%, p = 0.752), the guideline questions Sect. (49.4% vs. 61.4%, p = 0.140), and the social media platform questions Sect. (82.5% vs. 90%, p = 0.335), the completely correct answers rates were similar. There was a moderate positive correlation between ChatGPT and Gemini chatbots' answers (r = 0.633, p < 0.001). Reproducibility rates of answers to questions were 91.3% in ChatGPT and 92% in Gemini (p = 0.710). According to Cohen's kappa test, there was a substantial inter-rater agreement for both ChatGPT (κ = 0.720) and Gemini (κ = 0.704). ChatGPT and Gemini successfully answered CDC questions and social media platform questions, but the correct answer rates were insufficient for guideline questions.
Collapse
Affiliation(s)
- Meryem Sahin Ozdemir
- Department of Infectious Diseases and Clinical Microbiology, Basaksehir Cam and Sakura City Hospital, Istanbul, 34480, Turkey
| | - Yusuf Emre Ozdemir
- Department of Infectious Diseases and Clinical Microbiology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, 34140, Turkey.
| |
Collapse
|
43
|
Chiu CY, Razonable RR, Yao JD, Watt KD, Chesdachai S. Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study. Hepatol Commun 2025; 9:e0611. [PMID: 39670867 PMCID: PMC11637744 DOI: 10.1097/hc9.0000000000000611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2024] [Accepted: 11/11/2024] [Indexed: 12/14/2024] Open
Abstract
BACKGROUND Diagnostic uncertainty caused by the low positive predictive value of HEV-specific IgM antibody (Ab) testing in a low-prevalence setting. We investigated the utility of a two-step HEV IgM Ab testing approach for diagnosing HEV infection. METHODS We retrospectively reviewed all adults who underwent HEV IgM Ab and/or HEV RNA testing from July 2013 through June 2023 at Mayo Clinic. Two-step HEV IgM testing involved initial testing using recomWell HEV IgM ELISA (Mikrogen, Neuried, Germany), with reflex to recomLine HEV IgM Strip (Mikrogen, Neuried, Germany) on all recomWell HEV IgM-reactive or IgM-equivocal specimens, as recomLine HEV IgM has higher specificity than recomWell HEV IgM but is more labor-intensive. RESULTS A total of 1640 patients had HEV IgM Ab or HEV RNA testing, including 1293 (79%) with only HEV IgM Ab testing, 213 (13%) with only HEV RNA testing, and 134 (8%) with both HEV IgM Ab and HEV RNA testing. Eighteen HEV infections were diagnosed with acute (N=16) and chronic (N=2) infections. Two-step IgM Ab testing did not identify 2 solid organ transplant recipients with chronic HEV infection. In acute HEV infection with HEV viremia, 3 out of 4 patients (2 solid organ transplant recipients and 1 patient with Guillain-Barre syndrome) were treated with ribavirin. CONCLUSIONS A two-step HEV IgM Ab test may accurately diagnose acute HEV infection in immunocompetent persons. However, this approach fails to identify chronic HEV infection in immunocompromised individuals who need HEV RNA testing to establish the diagnosis.
Collapse
Affiliation(s)
- Chia-Yu Chiu
- Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA
- Department of Medicine, Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Raymund R. Razonable
- Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Joseph D. Yao
- Department of Laboratory Medicine and Pathology, Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Kymberly D. Watt
- Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| | - Supavit Chesdachai
- Department of Medicine, Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
44
|
Gomes CTDO, Mariz CA, Batista AD, Morais CNLD, Araújo L, Sá Barreto AVM, Gomes-Gouvêa MS, Domingues AL, Lopes EP. Seroprevalence of Hepatitis E Virus Among Schistosomiasis mansoni Patients Residing in Endemic Zone in Brazil. Trop Med Infect Dis 2024; 9:310. [PMID: 39728837 DOI: 10.3390/tropicalmed9120310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2024] [Revised: 12/14/2024] [Accepted: 12/17/2024] [Indexed: 12/28/2024] Open
Abstract
The occurrence of hepatitis E virus (HEV) in patients with Schistosomiasis mansoni (SM) is still poorly understood in Brazil. The objective of this study was to estimate the seroprevalence of anti-HEV IgG in patients with SM and its association with the periportal fibrosis (PPF), assessed by serum markers and ultrasound criteria. This cross-sectional study was carried out in an endemic area in Pernambuco, Brazil, with schistosomal patients who underwent coproscopic survey. Anti-HEV antibody IgG were evaluated by using ELISA (Euroimmun®, Lübeck, Germmany). In positive cases, HEV-RNA was tested by using real-time PCR. Among the 286 patients (60.8% women; 56% 18-44 years), 116 (40.6%) had advanced PPF (Niamey pattern D/E/F). Anti-HEV IgG was positive in 15 (5.24%), and all were HEV-RNA negative. Anti-HEV IgG was more frequent in patients with an advanced PPF (D/E/F) pattern (p = 0.034) and those with the largest spleen diameter (p = 0.039). In this study, the occurrence of anti-HEV IgG in patients with SM was higher than described in the same region and more frequent among patients with evidence of advanced liver fibrosis.
Collapse
Affiliation(s)
| | - Carolline Araujo Mariz
- Department of Parasitology, Aggeu Magalhães Institute, Fiocruz, Recife 50740-465, PE, Brazil
- Faculdade de Medicina de Olinda (FMO), Olinda 53030-030, PE, Brazil
| | - Andrea Dória Batista
- Gastroenterology Division, Hospital das Clínicas/EBSERH, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
- Department of Internal Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
| | | | - Lílian Araújo
- Gastroenterology Division, Hospital das Clínicas/EBSERH, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
| | | | - Michele Soares Gomes-Gouvêa
- Laboratory of Gastroenterology and Tropical Hepatology (LIM-07), Institute of Tropical Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-000, SP, Brazil
| | - Ana Lúcia Domingues
- Postgraduate Program in Tropical Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-420, PE, Brazil
- Gastroenterology Division, Hospital das Clínicas/EBSERH, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
| | - Edmundo Pessoa Lopes
- Postgraduate Program in Tropical Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-420, PE, Brazil
- Gastroenterology Division, Hospital das Clínicas/EBSERH, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
- Department of Internal Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-901, PE, Brazil
| |
Collapse
|
45
|
Fan Z, Xu L, Cao Y, Liu T, Tian Y, Pan Z, Mo Y, Wang X, Zhu X, Gao Y, Zhang X, Pan CQ, Wang L, Ren F. One-Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point-of-Care Testing. J Med Virol 2024; 96:e70115. [PMID: 39704190 DOI: 10.1002/jmv.70115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 11/10/2024] [Accepted: 11/26/2024] [Indexed: 12/21/2024]
Abstract
Hepatitis E virus (HEV) poses a serious threat to both public health and animal food safety, thereby highlighting the demands for rapid, sensitive, and easy-to-use detection. This study aimed to develop a One-Pot assay using CRISPR/Cas13a for detecting HEV RNA, suitable for point-of-care testing (POCT) in resource-limited settings. CRISPR/Cas13a combined with reverse transcription polymerase chain reaction (RT-PCR) and reverse transcription recombinase-aided amplification (RT-RAA) was applied to a One-Pot assay device. Additionally, a large cohort of HEV-infected patient (154) and animal (104) specimens was utilized for validation. The RT-PCR/RT-RAA + CRISPR/Cas13a assays for HEV RNA detection (genotypes: HEV-1, HEV-3, and HEV-4) were established, optimized, and validated, achieving a limit of detection (LoD) of 1 copy/μL and 100% specificity. In the application validation for HEV infection, the positive rates of the RT-PCR + CRISPR and RT-RAA + CRISPR assays were 98.6% and 89.6% for patients, and 96.6% and 88.8% for animals, respectively, which were superior to those of RT-qPCR. Furthermore, sample rapid lysis, reagent lyophilization, and the One-Pot device were integrated to construct a One-Pot assay with an LoD of 102 copies/μL. Despite slight decreases in sensitivity, the One-Pot assay significantly reduces the assay time to 35 min, making it easy to perform, minimizing contamination, and meeting the requirements for screening. We developed a One-Pot assay of HEV RNA using the CRISPR/Cas13a which effectively realizes a POCT test and maximizes the impetus for POCT implementation and shows potential as a valuable tool for detecting and monitoring HEV infection.
Collapse
Grants
- This study was supported by the National Natural Science Foundation of China (82002243, 82100653), Key Projects of the Beijing Municipal Education Commission's Science and Technology Plan (KZ202010025035), Chinese Institutes for Medical Research, Beijing (Grant No. CX24PY23), Beijing Hospitals Authority Youth Programme (QML20201702), Talent Cultivation Plan of Climbing the Peak of Beijing Municipal Hospital Administration (DFL20221503), Beijing Natural Science Foundation-Changping Innovation Joint Fund (L234046), Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University (CCMU2023ZKYXZ003), High-Level Public Health Technical Talents Project of Beijing (Subject Leaders-02-13, xuekegugan-03-48).
Collapse
Affiliation(s)
- Zihao Fan
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Ling Xu
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Yaling Cao
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Tianxu Liu
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People's Republic of China
| | - Yuan Tian
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Zhenzhen Pan
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Yinkang Mo
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Xinyu Wang
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Xianru Zhu
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Yao Gao
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Xiangying Zhang
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Calvin Q Pan
- NYU Langone Medical Center, New York University School of Medicine, New York City, New York, USA
| | - Lin Wang
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People's Republic of China
| | - Feng Ren
- Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China
| |
Collapse
|
46
|
Cao LC, Ha LNN, Giang TT, Tiep VM, Chau NTM, Phuong Anh TN, Duy PK, Nhan LP, Hoai NTT, Linh LTK, Hafza N, Bock CT, My TN, Sy BT, Toan NL, Song LH, Velavan TP. Characterization of zoonotic hepatitis E virus in domestic pigs and wild boar in Vietnam: Implications for public health. One Health 2024; 19:100857. [PMID: 39077329 PMCID: PMC11284544 DOI: 10.1016/j.onehlt.2024.100857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 07/08/2024] [Accepted: 07/08/2024] [Indexed: 07/31/2024] Open
Abstract
Vietnam's unprecedented demand for meat from livestock, including pigs and farmed wildlife, underscores the importance of understanding zoonotic reservoirs for hepatitis E virus (HEV). This study aimed to identify and characterize circulating zoonotic HEV in domestic pigs and wild boar to understand genotype frequencies, transmission dynamics, and associated human health burdens. Rectal swabs, feces, and liver samples from 415 pigs and 102 wild boars were collected across various farms and slaughterhouses in central and southern Vietnam and screened for HEV RNA using nested PCR. HEV RNA-positive samples underwent sanger sequencing and genotyping. Overall, 10% (n = 54/517) of samples were HEV RNA-positive, with wild boars exhibiting the highest HEV positivity rate at 25%, followed by domestic pigs at 7%. Southern Vietnam showed a higher HEV RNA positivity rate (20%) compared to central Vietnam (7%). Notably, rectal swabs demonstrated the highest positivity rate (15%), followed by feces (8%) and liver (4%). HEV-3a was the predominant genotype at 85%, followed by HEV-4b at 9% and HEV-3f at 6%. While HEV-3a was distributed across both central and southern Vietnam, HEV-3f was exclusively detected in central Vietnam, and HEV-4b was identified in wild boar in southern Vietnam. These findings underscore the substantial prevalence of HEV in wild boars, emphasizing their potential as crucial zoonotic reservoirs alongside domestic pigs. Further investigations involving occupationally exposed individuals in high-prevalence areas are warranted to evaluate the human health impact of zoonotic hepatitis E and inform preventive measures. Regular epidemiological studies are imperative for assessing the prevalence and transmission of zoonotic HEV infections among common reservoirs, thereby aiding in the prevention of spillover events within the community.
Collapse
Affiliation(s)
- Le Chi Cao
- Institute of Tropical Medicine, University of Tübingen, 72074, Tübingen, Germany
- Department of Parasitology, Hue University of Medicine and Pharmacy (HUMP), Hue University, 49000 Hue, Viet Nam
| | - Le Nguyen Nhat Ha
- School of Biotechnology, International University, Vietnam National University Ho Chi Minh City, 70000 Ho Chi Minh City, Viet Nam
| | - Tran Thi Giang
- Department of Parasitology, Hue University of Medicine and Pharmacy (HUMP), Hue University, 49000 Hue, Viet Nam
| | - Vo Minh Tiep
- Department of Parasitology, Hue University of Medicine and Pharmacy (HUMP), Hue University, 49000 Hue, Viet Nam
| | - Ngo Thi Minh Chau
- Department of Parasitology, Hue University of Medicine and Pharmacy (HUMP), Hue University, 49000 Hue, Viet Nam
| | - Ton Nu Phuong Anh
- Department of Parasitology, Hue University of Medicine and Pharmacy (HUMP), Hue University, 49000 Hue, Viet Nam
| | - Pham Khanh Duy
- School of Biotechnology, International University, Vietnam National University Ho Chi Minh City, 70000 Ho Chi Minh City, Viet Nam
| | - Le Phuc Nhan
- School of Biotechnology, International University, Vietnam National University Ho Chi Minh City, 70000 Ho Chi Minh City, Viet Nam
| | - Nguyen Thi Thu Hoai
- School of Biotechnology, International University, Vietnam National University Ho Chi Minh City, 70000 Ho Chi Minh City, Viet Nam
- Research Center for Infectious Diseases, International University, Vietnam National University Ho Chi Minh City, 70000, Ho Chi Minh City, Viet Nam
| | - Le Thi Kieu Linh
- Institute of Tropical Medicine, University of Tübingen, 72074, Tübingen, Germany
| | - Nourhane Hafza
- Institute of Tropical Medicine, University of Tübingen, 72074, Tübingen, Germany
| | - C. Thomas Bock
- Division of Viral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany
| | - Truong Nhat My
- Vietnamese-German Center for Medical Research (VG-CARE), 10000 Hanoi, Viet Nam
- 108 Military Central Hospital, 10000 Hanoi, Viet Nam
| | - Bui Tien Sy
- Vietnamese-German Center for Medical Research (VG-CARE), 10000 Hanoi, Viet Nam
- 108 Military Central Hospital, 10000 Hanoi, Viet Nam
| | - Nguyen Linh Toan
- Vietnamese-German Center for Medical Research (VG-CARE), 10000 Hanoi, Viet Nam
- Vietnam Military Medical University, 10000 Hanoi, Viet Nam
| | - Le Huu Song
- Vietnamese-German Center for Medical Research (VG-CARE), 10000 Hanoi, Viet Nam
- 108 Military Central Hospital, 10000 Hanoi, Viet Nam
| | - Thirumalaisamy P. Velavan
- Institute of Tropical Medicine, University of Tübingen, 72074, Tübingen, Germany
- Vietnamese-German Center for Medical Research (VG-CARE), 10000 Hanoi, Viet Nam
- Faculty of Medicine, Duy Tan University, 55000 Da Nang, Viet Nam
| |
Collapse
|
47
|
Borghi M, Graziani A, Marini D, Madonna E, Villano U, Suffredini E, Vicenza T, Mataj E, Bruni R, Ciccaglione AR, Camilloni B, Bozza S. Case of Fatal Hepatitis Related to HEV-3 Infection in Central Italy. Viruses 2024; 16:1869. [PMID: 39772179 PMCID: PMC11680277 DOI: 10.3390/v16121869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Revised: 11/27/2024] [Accepted: 11/28/2024] [Indexed: 01/11/2025] Open
Abstract
Hepatitis E virus (HEV) is a global health problem, causing an estimated 20 million infections annually. Thus, the management of HEV requires special consideration. In developed countries, hepatitis E is mainly recognized as a foodborne disease (mainly transmitted via undercooked meat consumption) that is generally caused by genotype 3 and 4 circulating in various animals, including pigs and wild boars. The current absence of officially recognized protocols for the analysis of HEV in foods and the lack of awareness of this disease among healthcare workers, together with the high percentage of asymptomatic cases, make HEV infection highly underestimated. Most HEV-3 infections in immunocompetent individuals are self-limited. Nevertheless, the possibility of serious forms of liver disease, especially in patients with co-morbidities, should be considered because it can lead to a fatal outcome. Here, we report a case of fatal hepatitis related to HEV-3 infection in a 67-year-old male patient with underlying chronic liver disease (CLD) and living in a region where a high prevalence and genetic heterogeneity of HEV-3 in wild boar has been recently demonstrated. Our case report describes the interdisciplinary approach used (from the diagnosis to the virus phylogenetic characterization) in order to improve epidemiologic HEV surveillance in central Italy.
Collapse
Affiliation(s)
- Monica Borghi
- Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche, 06126 Perugia, Italy;
| | - Alessandro Graziani
- Microbiology and Clinical Microbiology Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy; (A.G.); (S.B.)
| | - Daniele Marini
- Microbiology Unit, Santa Maria della Misericordia Hospital, 06132 Perugia, Italy;
| | - Elisabetta Madonna
- Department of Infectious Diseases, Unit of Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.M.); (U.V.); (R.B.); (A.R.C.)
| | - Umbertina Villano
- Department of Infectious Diseases, Unit of Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.M.); (U.V.); (R.B.); (A.R.C.)
| | - Elisabetta Suffredini
- Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.S.); (T.V.)
| | - Teresa Vicenza
- Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.S.); (T.V.)
| | - Elida Mataj
- Institute of Public Health (ISHP), 1000 Tirana, Albania;
| | - Roberto Bruni
- Department of Infectious Diseases, Unit of Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.M.); (U.V.); (R.B.); (A.R.C.)
| | - Anna Rita Ciccaglione
- Department of Infectious Diseases, Unit of Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; (E.M.); (U.V.); (R.B.); (A.R.C.)
| | - Barbara Camilloni
- Microbiology and Clinical Microbiology Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy; (A.G.); (S.B.)
- Microbiology Unit, Santa Maria della Misericordia Hospital, 06132 Perugia, Italy;
| | - Silvia Bozza
- Microbiology and Clinical Microbiology Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy; (A.G.); (S.B.)
- Microbiology Unit, Santa Maria della Misericordia Hospital, 06132 Perugia, Italy;
| |
Collapse
|
48
|
da Silva LL, Leon LAA, da Cruz Moreira O, da Costa Nunes Pimentel Coelho WL, da Costa VD, Ivantes CAP, Pollo-Flores P, Lewis-Ximenez LL, de Paula VS, Villar LM. Serum microRNA 143 and 223 Gene Expression Profiles as Potential Biomarkers in Individuals with Hepatitis and COVID-19. Viruses 2024; 16:1734. [PMID: 39599849 PMCID: PMC11598994 DOI: 10.3390/v16111734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Revised: 10/25/2024] [Accepted: 10/28/2024] [Indexed: 11/29/2024] Open
Abstract
MicroRNAs (miRNAs) can act as biomarkers and descriptors of the association between infections and other diseases, such as hepatitis and COVID-19. This study aims to investigate the role of miRNA serum expression according to laboratory data concerning hepatitis and COVID-19. Seventy individuals recruited in Southern and Southeastern Brazil donated serum samples and were divided into four groups: (i) 20 negative subjects, (ii) 20 presenting hepatitis, (iii) 19 with COVID-19 and (iv) 11 with hepatitis and COVID-19. Three miRNAs (miR-122, miR-143 and miR-223) were evaluated using real-time PCR. Hematological and biochemical markers were also analyzed. MiR-143 and miR-223 were downregulated among the hepatitis/COVID-19 group (p < 0.05). A positive correlation was observed between miR-223 and lymphocytes. There was a negative correlation between alanine transaminase (ALT) and aspartate transaminase (AST) for miR-143 and miR-223 and gamma-glutamyl transferase (GGT), alkaline phosphatase (AP) and neutrophil/lymphocyte ratio (NLR) only for miR-223 (p < 0.05). For hepatic fibrosis (FIB-4), miR-122 and miR-143 had a greater association and miR-223 was more associated with a history of vaccination against COVID-19. MicroRNAs 143 and 223 could be useful as biomarkers for hepatitis coinfection with COVID-19.
Collapse
Affiliation(s)
- Lucas Lima da Silva
- National Reference Laboratory for Viral Hepatitis, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (V.D.d.C.); (L.L.L.-X.)
| | - Luciane Almeida Amado Leon
- Technological Development Laboratory, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (L.A.A.L.); (W.L.d.C.N.P.C.)
| | - Otacílio da Cruz Moreira
- Molecular Virology and Parasitology Laboratory, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (O.d.C.M.); (V.S.d.P.)
| | | | - Vanessa Duarte da Costa
- National Reference Laboratory for Viral Hepatitis, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (V.D.d.C.); (L.L.L.-X.)
| | | | - Priscila Pollo-Flores
- Department of Clinical Medicine, Fluminense Federal University, Niterói 24220-000, RJ, Brazil;
| | - Lia Laura Lewis-Ximenez
- National Reference Laboratory for Viral Hepatitis, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (V.D.d.C.); (L.L.L.-X.)
| | - Vanessa Salete de Paula
- Molecular Virology and Parasitology Laboratory, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (O.d.C.M.); (V.S.d.P.)
| | - Livia Melo Villar
- National Reference Laboratory for Viral Hepatitis, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil; (V.D.d.C.); (L.L.L.-X.)
| |
Collapse
|
49
|
Pawlotsky JM. Virological markers for clinical trials in chronic viral hepatitis. JHEP Rep 2024; 6:101214. [PMID: 39524203 PMCID: PMC11550202 DOI: 10.1016/j.jhepr.2024.101214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2024] [Revised: 08/30/2024] [Accepted: 09/02/2024] [Indexed: 11/16/2024] Open
Abstract
Chronic hepatitis virus infections remain a major public health problem, despite significant therapeutic advances over the past two decades. Considerable progress has been made in the treatment of chronic viral hepatitis, but continued efforts are needed to develop and bring to market new drugs to fill the gaps in the current therapeutic armamentarium. Thus, clinical trials to assess the safety and efficacy of these new therapeutic approaches, including the selection of reliable and objective treatment endpoints, are still needed. Virological biomarkers play an important role in the diagnosis, monitoring, and evaluation of antiviral treatment efficacy. They are often used as primary or secondary endpoints in the evaluation of new treatments for chronic viral hepatitis. However, these markers are not all equally informative. The aim of this review article is to provide a comprehensive overview of the available virological tests for chronic viral hepatitis due to hepatitis B, D, C and E viruses, the information they provide and lack, the specific challenges associated with each, and their use in clinical trials of new treatments.
Collapse
Affiliation(s)
- Jean-Michel Pawlotsky
- National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor (AP-HP), Université Paris-Est, Créteil, France
- Team “Viruses, Hepatology, Cancer”, Institut Mondor de Recherche Biomédicale, INSERM U955, Université Paris-Est, Créteil, France
| |
Collapse
|
50
|
Dong R, Xue H, Chen L, Jin W, Luo Z, Shen C, Huang L, Shao J, Wang J. Associations of Lipid Profiles With the Onset of HEV-Related Acute Liver Failure: A Multicenter Cohort Study. J Med Virol 2024; 96:e70033. [PMID: 39529488 DOI: 10.1002/jmv.70033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Revised: 09/21/2024] [Accepted: 10/17/2024] [Indexed: 11/16/2024]
Abstract
Hepatitis E virus (HEV) is one of the major etiologies for acute liver failure. This multicenter retrospective cohort study aimed to investigate the associations of lipid profiles with the risk of HEV-related acute liver failure (HEV-ALF) among hospitalized patients with acute hepatitis E. A total of 1061 participants were obtained from three tertiary medical centers in Jiangsu, China, between February 2018 and May 2024. Univariate and multivariate Cox regression models were constructed to assess the associations between lipid profiles and the risk of HEV-ALF onset. The time-dependent area under the receiver-operating-characteristic curve (AUROC) and decision curve analysis were used to further evaluate the predictive value of blood lipids. After adjusting for potential confounders, total cholesterol (HR = 0.535, 95% CI: 0.437-0.656, p < 0.001), high-density lipoprotein-cholesterol (HR = 0.065, 95% CI: 0.027-0.154, p < 0.001), low-density lipoprotein-cholesterol (HR = 0.653, 95% CI: 0.512-0.833, p = 0.001), and apolipoprotein A (ApoA) (HR = 0.006, 95% CI: 0.002-0.020, p < 0.001) were significantly associated with a reduced risk of HEV-ALF. Moreover, blood ApoA exhibited excellent discrimination ability and net benefit for predicting 7-day (AUROC = 82.47%, 95% CI: 77.92-87.02) and 14-day (AUROC = 78.81%, 95% CI: 74.13-83.49) HEV-ALF onset. The findings may provide further evidence on the progression of HEV infection and future risk prediction.
Collapse
Affiliation(s)
- Rui Dong
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, China
| | - Hong Xue
- Department of Liver Disease, The Third Affiliated Hospital of Nantong University, Nantong, China
| | - Lin Chen
- Nantong Institute of Liver Disease, The Third Affiliated Hospital of Nantong University, Nantong, China
| | - Wenjuan Jin
- Department of Infectious Disease, The Affiliated Suzhou Ninth People's Hospital of Soochow University, Suzhou, China
| | - Zhenghan Luo
- Department of Infectious Disease Prevention and Control, Huadong Research Institute for Medicine and Biotechniques, Nanjing, China
| | - Chao Shen
- Department of Immunization Program, Nanjing Municipal Center for Disease Control and Prevention, Nanjing, China
| | - Lili Huang
- NHC Key Laboratory of Contraceptives Vigilance and Fertility Surveillance/Jiangsu Health Development Research Center, Nanjing, China
| | - Jianguo Shao
- Department of Gastroenterology, The Third Affiliated Hospital of Nantong University, Nantong, China
| | - Jie Wang
- Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, China
| |
Collapse
|